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2	
ABSTRACT	
	
A	core	cleavage	complex	(CCC)	consisting	of	CPSF73,	CPSF100	and	Symplekin	 is	
required	for	co-transcriptional	3’	end	processing	of	all	metazoan	pre-mRNAs,	yet	little	is	
known	 about	 the	 in	 vivo	 molecular	 interactions	 within	 this	 complex.	 The	 CCC	 is	 a	
component	 of	 two	distinct	 complexes,	 the	 cleavage/polyadenylation	 complex	 and	 the	
complex	that	processes	non-polyadenylated	histone	pre-mRNAs.	RNAi-depletion	of	CCC	
factors	in	Drosophila	culture	cells	causes	reduction	of	CCC	processing	activity	on	histone	
mRNAs,	resulting	in	read	through	transcription.	In	contrast,	RNAi-depletion	of	factors	only	
required	for	histone	mRNA	processing	allows	use	of	downstream	cryptic	polyadenylation	
signals	to	produce	polyadenylated	histone	mRNAs.	We	used	Dmel-2	tissue	culture	cells	
stably	expressing	 tagged	CCC	components	 to	determine	 that	amino	acids	272-1080	of	
Symplekin	and	the	C-terminal	~200	amino	acids	of	both	CPSF73	and	CPSF100	are	required	
for	efficient	CCC	formation	in	vivo.	Additional	experiments	reveal	that	the	C-terminal	241	
amino	acids	of	CPSF100	are	sufficient	 for	histone	mRNA	processing	 indicating	that	the	
first	524	amino	acids	of	CPSF100	are	dispensable	 for	both	CCC	 formation	and	histone	
mRNA	3’	 end	processing.	 CCCs	 containing	deletions	of	 Symplekin	 lacking	 the	 first	 271	
amino	acids	resulted	in	a	significantly	increased	use	of	downstream	polyadenylation	sites	
for	histone	mRNA	3’	end	processing	similar	to	RNAi-depletion	of	histone	specific	3’	end	
processing	 factors	 FLASH,	 SLBP	 and	 U7	 snRNA.	 We	 propose	 a	 model	 in	 which	 CCC	
formation	is	mediated	by	CPSF73,	CPSF100	and	Symplekin	C-termini,	and	the	N-terminal	
region	of	Symplekin	facilitates	co-transcriptional	3’	end	processing	of	histone	mRNAs.		
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Introduction	
	
Regulation	 of	 gene	 expression	 is	 vital	 for	 proper	 cellular	 differentiation,	 cellular	
proliferation,	 and	 organismal	 development.	 At	 the	 post-transcriptional	 level	 this	
regulation	involves	multiple	steps,	including	proper	processing	of	pre-mRNAs.	Metazoan	
pre-mRNAs	 require	 extensive	 processing	 before	 becoming	mature	mRNAs,	 and	 these	
processing	events	include	5’	end	modification,	splicing,	and	3’-end	processing.	Cleavage	
followed	by	polyadenylation	is	a	vital	processing	event	for	all	non-histone	mRNAs.	3’-end	
processing	 of	 canonical	 poly(A)	 pre-mRNAs	 involves	 a	 single	 endonucleolytic	 cleavage	
event	between	an	upstream	conserved	AAUAAA	hexanucleotide	sequence	and	a	U-	or	
G/U-rich	downstream	element.	 Interestingly,	maturation	of	histone	pre-mRNAs,	which	
are	not	polyadenylated,	requires	only	a	single	cleavage	event	between	an	upstream	stem	
loop	 (SL)	 analogous	 to	 the	 AAUAAA	 in	 canonical	 poly(A)	 mRNAs,	 and	 the	 histone	
downstream	element	(HDE).	These	different	cis	elements	are	responsible	for	recruiting	
either	histone	or	canonical	poly(A)	mRNA	specific	processing	factors.	The	SL	 in	histone	
mRNAs	is	bound	by	the	stem	loop	binding	protein	(SLBP)	while	the	HDE	interacts	with	the	
U7snRNA	 component	 of	 the	 U7	 small	 nuclear	 ribonucleic	 protein	 particle	 (snRNP)	
(Marzluff	et	al.	2008).	General	and	histone	specific	3’-end	processing	factors	are	recruited	
to	the	histone	pre-mRNA	via	the	U7snRNP,	presumably	due	to	an	interaction	between	
Lsm11	 and	 FLASH	 (Sabath	 et	 al.	 2013).	 The	 AAUAAA	 hexanucleotide	 characteristic	 of	
canonical	 poly(A)	 mRNAs	 binds	 cleavage	 and	 polyadenylation	 stimulation	 factor	 30	
(CPSF30)	and	WDR33	(Schönemann	et	al.	2014).	Cleavage	stimulation	factor	64	(CstF64)	
contacts	the	less	conserved	G-	or	G/U	rich	element	(Takagaki	and	Manley	1997).	While	
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both	types	of	mRNAs	use	unique	proteins,	an	essential	core	cleavage	complex	comprised	
of	 CPSF73,	 CPSF100,	 and	 Symplekin	 is	 required	 for	 proper	 processing	 of	 all	metazoan	
mRNAs.	CPSF73	 is	 the	enzyme	 responsible	 for	 catalyzing	 the	endonucleolytic	 cleavage	
reaction	(Mandel	et	al.	2006),	and	CPSF100	forms	a	heterodimer	with	CPSF73.	Symplekin	
acts	as	a	scaffolding	protein	onto	which	other	cleavage	and	polyadenylation	proteins	bind	
(Dominski	et	al.	2005;	Takagaki	and	Manley	2000).	
Poly(A)	pre-mRNA	3’-end	processing:		
	
At	the	post-transcriptional	 level	proper	gene	expression	 is	highly	regulated	and	
involves	 proper	 processing	 of	 pre-mRNAs.	 Metazoan	 pre-mRNAs	 require	 extensive	
processing	 before	 becoming	 mature	 mRNAs	 that	 can	 be	 translated	 into	 protein	 via	
ribosomes	 located	 in	 the	 cytoplasm.	 Pre-mRNA	 processing	 events	 include	 5’-end	
modification,	 intron	 splicing,	 and	 3’-end	 processing.	 Pre-mRNA	 5’-end	 modification	
creates	the	5’-cap	present	on	all	mature	mRNAs.		Addition	of	the	mRNA	cap	occurs	in	the	
nucleus	where	by	a	GTP	molecule	is	attached	to	the	first	encoded	nucleotide	(N1)	of	a	
transcript.	The	GTP	molecule	is	attached	to	the	first	nucleotide	via	an	unusual	linkage	in	
which	 the	 5ʹ	 hydroxyl	 group	 of	 the	GTP	 is	 connected	 to	 the	 5ʹ	 hydroxyl	 group	 of	 the	
nucleotide	by	three	phosphate	groups	(Gu	and	Lima	2005;	Adams	and	Cory	1975).		The	
most	 well-characterized	 methyl	 group	 is	 found	 on	 the	 N7	 position	 of	 the	 essential	
guanosine.	Methylation	of	N7	is	required	for	mRNA	export	and	subsequent	recognition	of	
the	5’-cap	by	the	eukaryotic	translation	initiation	factor	4E	(eIF4E)(Gu	and	Lima	2005).	In	
vitro	 experiments	 reveal	 that	 lack	 of	 this	 N7	 methyl	 group	 significantly	 reduces	
translational	efficiency	(Muthukrishnan	et	al.	1975).		
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Pre-mRNA	3’-end	cleavage	followed	by	polyadenylation	is	a	vital	processing	event	
for	all	non-histone	mRNAs.	3’-end	processing	of	canonical	poly(A)	pre-mRNAs	involves	a	
single	 endonucleolytic	 cleavage	 event.	 Cleavage	 occurs	 within	 the	 mRNA’s	 3’-
Untranslated	region	(UTR)	and	relies	on	the	presence	of	two	conserved	cis	elements:	an	
upstream	conserved	AAUAAA	hexanucleotide	sequence	and	a	U-	or	G/U-rich	downstream	
element.	 These	 cis	 elements	 bind	 specific	 protein	 factors	 that	 subsequently	 recruit	
numerous	 protein	 complexes	 required	 for	 proper	 canonical	 poly(A)	 3’-end	 mRNA	
processing.	The	AAUAAA	hexanucleotide	characteristic	of	canonical	poly(A)	mRNAs	binds	
CPSF30	 and	WDR33	 (2014;	 Schönemann	 et	 al.	 2014).	 Cleavage	 stimulation	 factor	 64	
(CstF64)	contacts	the	less	conserved	G-	or	G/U	rich	element	(Takagaki	and	Manley	1997).	
An	 essential	 core	 cleavage	 complex,	 here	 termed	 the	 CCC,	 is	 required	 for	 proper	
processing	of	all	metazoan	mRNAs.	This	complex	is	comprised	of	three	proteins:	CPSF73,	
CPSF100,	 and	 Symplekin.	 CPSF73	 is	 the	 enzyme	 responsible	 for	 catalyzing	 the	
endonucleolytic	cleavage	reaction	(Mandel	et	al.	2006;	2004;	2005),	and	CPSF100	forms	
a	heterodimer	with	CPSF73.	 Symplekin	 acts	 as	 a	 scaffolding	protein	onto	which	other	
cleavage	and	polyadenylation	proteins	bind	(Dominski	et	al.	2005;	Takagaki	and	Manley	
2000).	
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Figure	1-A:	Polyadenylated	mRNA	3’-end	processing	
	
	
		
 
 
 
 
	
	
	
	
 
Polyadenylated	mRNA	3’-end 
AAUAAA U-	or	G/U-rich	DSE 
5’ 3’ 
(10-30	nt) (~30	nt) 
3’ 
5’ 
AAUAAA 3‘-Poly(A)	tail 
U-	or	G/U-rich	DSE 5’ 
Single	Nucleotides 
Polyadenylated	 mRNA	 3’-end	 processing.	 Polyadenylated	 mRNAs	 have	 two	
conserved	 cis	 elements:	 An	 ‘AAUAAA’	 hexanucleotide	 sequence	 upstream	 of	 the	
cleavage	 site	 and	 a	 U-	 or	 G/U-rich	 downstream	 element	 (DSE).	 Cleavage	 occurs	
between	these	two	elements.	The	upstream	product	is	polyadenylated	at	its	3’-end	
while	the	downstream	product	is	degraded	to	single	nucleotides.			
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Alternative	Cleavage	and	Polyadenylation:	
 
The 3’-end processing machinery itself is a massive protein complex containing 
over 70 loosely bound polypeptides (Shi et al. 2009). Several	 of	 these	 3’-end	mRNA	
processing	factors	have	been	shown	to	regulate	alternative	cleavage	and	polyadenylation	
(APA).	APA	is	a	cellular	process	that	only	recently	has	been	recognized	as	an	important	
component	 of	 post-transcriptional	 gene	 regulation	 thanks	 to	 the	 advent	 of	 high-
throughput	 sequencing	 techniques	 and	 subsequent	 mapping	 programs	 capable	 of	
detecting	the	presence	of	multiple	polyadenylation	signals	(PAS’s)	within	a	given	protein	
encoding	gene.	This	gave	rise	to	the	discovery	of	both	the	prevalence	of	APA	and		cell	
specific		patterns/preferences	of	each	APA	transcript	(Jenal	et	al.	2012;	Martin	et	al.	2012;	
Yao	et	al.	2012).		
Alteration	of	 the	 coding	 sequence	enables	APA	 to	 regulate	 the	 function	of	 the	
affected	 genes,	 whereas	 altering	 the	 length	 of	 the	 3’	 UTR	 enables	 APA	 to	 affect	 the	
stability,	cellular	localization,	and/or	translation	efficiency	of	the	target	RNAs(Elkon	et	al.	
2013).	The	3’	UTR	is	known	to	be	the	target	of	regulatory	factors	such	as	microRNAs	and	
RNA	binding	proteins	[13,14].	Thus	altering	the	length	of	this	potential	regulatory	region	
can	have	a	significant	impact	on	cellular	function	(refer	to	Figure	1-C).	Consider	cells	that	
utilize	proximal	poly(A)	sites	on	mRNA	isoforms	of	the	proto-oncogenes	cyclin	D2	(CCND2)	
and	insulin-like	growth	factor	2	mRNA	binding	protein	1	(IGF2BP1).	These	short	isoforms	
of	the	gene	no	longer	possess	let-7	and/or	miR-15/16	target	sites	and	as	a	result	are	either	
more	proliferative	(CCND2)	or	oncogenic	(IGF2BP1)	than	those	transcripts	expressing	the	
longer	mRNA	isoforms(Mayr	and	Bartel	2009).		APA	has	also	been	shown	to	affect	cellular	
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localization	of	proteins,	as	can	be	seen	 in	 the	case	of	brain-derived	neurotropic	 factor	
(BDNF).	Proximal	APA	of	BDNF	generates	a	shorter	mRNA	isoform	that	is	confined	to	the	
neuronal	soma	while	the	distal	APA	site	produces	a	longer	isoform	that	is	localized	to	the	
dendrites	where	it	is	translated(An	et	al.	2008).		
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Figure	1-B:	The	main	Alternative	Polyadenylation	Patterns	
	 	
	 	
Schematic	 illustration	of	 the	main	Alternative	Polyadenylation	Patterns.	APA	can	
occur	at	tandem	3’-UTR	sites,	at	alternative	terminal	exons,	at	intronic	sites,	and	at	
exonic	 coding	 sequence	 sites	 (CDS).	 The	 top	 illustration	 represents	 the	 pre-mRNA	
transcript	 and	 the	 location/presence	 of	 multiple	 polyadenylation	 sites	 (PAS).	 All	
illustrations	 below	 the	 primary	 pre-mRNA	 transcript	 represent	 the	 various	
patterns/locations	 of	 APA.	 The	 effects	 of	 APA	 are	 often	 gene	 specific	 and	 vary	
depending	on	where	the	APA	occurred.	Adapted	from	Gruber	et	al	(2014).	
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It	remains	unclear	how	general	mRNA	3’-end	processing	factors	regulate	APA	of	
specific	transcript	sets	and	why	distinct	APA	patterns	are	seen	in	different	mRNAs.	Recent	
global	studies	revealed	that	APA	is	dynamically	regulated	during	development,	and	de-
regulation	is	associated	with	a	number	of	diseases	(Di	Giammartino	et	al.	2011;	Shi	2012;	
Elkon	et	al.	2013;	Mueller	et	al.	2013;	Tian	and	Manley	2013).	Stem	cells	and	cancer	cells	
tend	 to	 favor	 proximal	 poly(A)	 sites	 (PAS),	 whereas	 differentiated	 or	 quiescent	 cells	
generally	use	distal	PAS	(Flavell	et	al.	2008;	Sandberg	et	al.	2008;	Ji	et	al.	2009;	Mayr	and	
Bartel	2009;	Shepard	et	al.	2011;	Elkon	et	al.	2012).	APA	regulators	and	3’	end	processing	
factors	appear	to	elicit	effects	that	are	cell-type	specific.	They	affect	embryonic	stem	cells	
by	regulating	specific	sets	of	mRNA	transcripts,	although	the	mechanism	of	this	is	unclear.
	 Fip1	has	been	identified	as	an	essential	3’	end-processing	factor	and	is	a	subunit	
of	CPSF.	As	such	 it	 is	 involved	 in	PAS	 recognition	and	 in	 recruiting	poly(A)	polymerase	
(PAP)	to	the	3’	end	processing	complex(Kaufmann	et	al.	2004).	Fip1	also	regulates	mRNA	
alternative	polyadenylation	in	embryonic	stem	cells	(ESCs)	as	determined	via	direct	RNA	
sequencing	and	mapping	of	RNA	poly(A)	sites	globally	(Lackford	et	al.	2014).				 	
	 The	addition	of	poly(A)	tails	to	mRNAs	requires	the	aid	of	poly(A)	binding	proteins	
(PABPs).	These	proteins	are	found	both	in	the	nucleus	and	in	the	cytoplasm.	The	poly(A)	
Binding	Protein	Nuclear	1	(PABPN1)	functions	during	poly(A)	tail	addition	to	mRNAs,	and	
in	vitro	studies	show	that	PABPN1	addition	to	CPSF/PAP	complexes	strongly	stimulates	
the	polyadenylation	reaction(Kühn	et	al.	2009)	(Wahle	1995).		
A	 study	by	 Jenal	et	al.	 shows	 that	PABPN1	modulates	APA	via	 suppressing	 the	
usage	of	weak	proximal	PASs.	This	is	evidence	that	PABPN1	acts	before	the	cleavage	and	
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polyadenylation	of	mRNAs	to	control	the	rate	of	proximal	PAS	usage(Jenal	et	al.	2012).	It	
was	also	found	that	PABPN1	knockdown	(KD)	induces	early	termination	of	Polymerase	II	
transcription.	 This	 supports	 the	 idea	 that	 reducing	 the	 level	 of	 PABPN1	 results	 in	 the	
activation	of	proximal	cleavage	site	usage	(refer	to	Figure	1-D)	(Jenal	et	al.	2012).	This	is	
the	opposite	of	what	was	found	for	Fip1	KD,	suggesting	the	two	proteins	are	differentially	
regulated	when	it	comes	to	APA.	Proximal	PAS	usage	is	not	a	consequence	of	activating	
the	3’-end	processing	machinery	globally,	indicating	that	PABPN1	alone	plays	a	direct	role	
in	suppressing	PAS-mediated	cleavage	at	proximal	sites(Jenal	et	al.	2012).	Selection	of	the	
distal	PAS	site	due	to	the	presence	of	PABPN1	then	allows	for	the	target	transcript	to	be	
regulated	by	its	full	3’	UTR	sequence(Jenal	et	al.	2012).	 In	addition	to	enhancement	of	
proximal	cleavage	site	usage,	loss	of	PABPN1	was	found	to	induce	global	3’UTR	shortening	
via	the	use	of	3’	end	sequencing,	and	KD	of	PABPN1	was	shown	to	promote	usage	of	non-
canonical	proximal	PASs	(Jenal	et	al.	2012).	
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Figure	1-C:	PABPN1	KD	Causes	a	shift	in	PAS	usage	
	
	
	
	
	
	
	
	A	UCSC	screenshot	showing	the	shift	in	PAS	usage	of	CCND1	in	PABPN1	KD	cells.	A	
RNA-sequencing	 study	 by	 Jenal	 et	 al.	 shows	 that	 PABPN1	 modulates	 APA	 via	
suppressing	the	usage	of	weak	proximal	PAS	(bottom	2	lines	of	the	figure;	top	4	lines	
are	 controls).	 Thus	 PABPN1	must	 act	 before	 the	 cleavage	 and	 polyadenylation	 of	
mRNAs	to	control	the	rate	of	proximal	PAS	usage.	Additionally,	PABPN1	KD	was	found	
to	induce	early	termination	of	Polymerase	lI	transcription.	This	supports	the	idea	that	
reducing	the	level	of	PABPN1	results	in	the	activation	of	proximal	cleavage	site	usage.	
Adapted	from	Jenal	et	al.	(2012)	
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Human	 loss	 of	 PABPN1	 results	 in	 a	 genome-wide	 enhancement	 of	 proximal	
cleavage	 site	 usage(Jenal	 et	 al.	 2012).	 Results	 from	 this	 study	 indicate	 that	 PABPN1	
suppresses	 APA	 sites	 and	 suggests	 that	 unbalanced	 APA	 is	 a	 causal	 factor	 in	
Oculopharyngeal	muscular	dystrophy	 (OPMD)(Jenal	 et	 al.	 2012).	 This	 is	 an	autosomal-
dominant	form	of	late-onset	slowly	progressive	myopathy	caused	by	short	expansions	of	
a	(GCG)6	triplet	repeat	to	(GCG)8-13	in	the	PABPN1	gene	(trePABPN1)	(Rüegg	et	al.	2005;	
Brais	et	al.	1998).	trePABPN1	causes	the	aggregation	of	nuclear	proteins	and	formation	
of	filamentous	nuclear	inclusions,	both	of	which	are	classical	signs	of	OPMD(Calado	et	al.	
2000).	This	evidence	supports	a	role	for	PABPN1	in	APA.	
Cleavage	Factor	I	(CFIm)	is	a	component	of	the	3’	end	processing	apparatus	and	is	
a	tetramer	composed	of	two	25	kDa	subunits	and	two	larger	polypeptides	of	59	or	68	kDa	
that	can	be	modified	via	methylation(Yang	et	al.	2011;	Coseno	et	al.	2008;	Martin	et	al.	
2010).	KD	of	CFIm68	induces	the	use	of	proximal	PAS,	as	seen	in	Figure	1-E,	mimicking	the	
behavior	observed	in	proliferating	stem	cells(Martin	et	al.	2012).	This	also	mimics	the	APA	
pattern	observed	for	PABPN1	KD.	Preliminary	A-seq	data,	which	is	a	sequencing	method	
that	enables	sequencing	of	mRNA	3’	ends	in	the	sense	direction	and	avoids	sequencing	
through	regions	of	As	or	Ts,	reveals	that	CFIm68	KD	leads	to	a	systemic,	transcriptome-
wide	shift	 toward	the	preferential	use	of	more	proximal	APA	sites(Martin	et	al.	2012).	
Cells	expressing	normal	levels	of	CFIm68	tend	to	skip	proximal	cleavage	sites.	This	begs	
the	question	of	how	the	distal	site	is	preferentially	chosen	over	the	proximal	site.	Previous	
studies	suggest	it	is	possible	that	stable	binding	of	CFIm68	at	the	distal	site	is	required	for	
proper	CPSF	 function	and	3’	end	processing.	Alternatively,	CFIm68	could	 interact	with	
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UGUA	motifs	upstream	of	the	two	PASs,	 looping	out	the	proximal	site	and	making	the	
distal	site	more	preferable	to	cleavage(Martin	et	al.	2012).		
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Effects	of	CF	Im68	siRNA	treatment	on	the	poly(A)	site	choice	(genome	browser	panel	
showing	the	A-seq	results):		KD	of	CFIm68	induces	the	use	of	proximal	PAS,	as	seen	in	
the	panel	above.	This	mimics	the	behavior	observed	in	proliferating	stem	cells.	This	
also	mimics	the	APA	pattern	observed	for	PABPN1	KD(Figure	1-C).	A-seq,	a	sequencing	
method	that	enables	sequencing	of	mRNA	3’	ends	in	the	sense	direction	and	avoids	
sequencing	through	regions	of	As	or	Ts,	data	shows	that	CFIm68	KD	(bottom	line	of	the	
above	genome	browser	panel)	leads	to	a	systemic,	transcriptome-wide	shift	in	APA	site	
usage	to	the	more	proximal	APA	site.	Adapted	from	Martin	et	al.	(2012)	
Figure	1-D:	CF	Im68	knockdown	alters	poly(A)	site	choice	based	on	A-seq	results	
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Cleavage	 stimulation	 factor	 64	 (CstF64)	 is	 a	 part	 of	 the	 CstF	 complex	 and	 an	
essential	pre-mRNA	processing	factor.	CstF64	and	CstF64τ	are	paralogs	of	each	other	and	
the	 two	 proteins	 have	 similar	 structural	 domains(Yao	 et	 al.	 2012).	 	 CstF64τ	 has	 been	
isolated	with	the	CstF	complex,	yet	its	precise	function	remains	unknown(Yao	et	al.	2012).	
CstF64τ	 may	 suffice	 for	 CstF	 complex	 formation	 and	 function	 when	 CstF64	 is	
downregulated,	 as	 CstF64τ	 has	 previously	 been	 shown	 to	 be	 essential	 for	
spermatogenesis	when	 CstF64	 is	 RNAi-depleted(Martin	 et	 al.	 2012;	 Dass	 et	 al.	 2007).	
These	results	suggest	that	the	two	proteins	have	redundant	functions,	with	CstF64τ	taking	
over	when	CstF64	is	absent(Martin	et	al.	2012).	CstF64	is	thought	to	be	a	general	3’	end	
processing	factor,	yet	study	results	indicate	that	CstF64	depletion	affects	the	APA	of	only	
a	specific	subset	of	genes(Yao	et	al.	2012).	However,	how	CstF64	regulates	APA	remains	
unknown(Yao	et	al.	2012).	CstF64	is	known	to	be	an	important	APA	regulator	in	specific	
situations	such	as	antibody	production	via	B-cells.	CstF64	protein	levels	increase	during	
B-cell	differentiation,	which	 leads	B-cells	 to	switch	 from	using	 the	strong	distal	PAS	 to	
using	the	weaker	proximal	PAS	in	the	pre-mRNA.	This	ultimately	leads	to	a	change	from	
the	 membrane	 bound	 form	 of	 the	 IgM	 antibody	 to	 the	 secreted	 form	 of	 the	
antibody(Takagaki	et	al.	1996;	Yao	et	al.	2012).	
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Figure	1-E:	Enriched	Sequence	Motifs	for	mRNA	3’-end	processing	
	
	
	
	
	
	
	
	
	
Sequence	 motifs	 that	 are	 most	 enriched	 in	 the	 binding	 sites	 of	 3’-end	 mRNA	
processing	factors.	Research	shows	that	the	RNA-binding	specificities	of	CstF64	and	its	
paralog	CstF64τ	overlap	one	another,	as	evidenced	by	their	enriched	sequence	motifs	
identified	in	Figure	1-E	above.	The	similarity	of	binding	sites	is	evidence	that	the	two	
factors	play	redundant	roles	in	APA	regulation.	Fip1,	a	component	of	the	CPSF	complex	
and	thus	a	3’-end	mRNA	processing	factor,	has	an	enriched	sequence	motif	matching	
that	 of	 canonical	 PASs.	More	 recent	 data	 identified	 Fip1	 as	 the	 protein	 factor	 that	
directly	binds	the	AAUAAA	PAS.		Adapted	from	Martin	et	al.	(2012)	
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Abundant	levels	of	CstF64	promote	proximal	PAS	usage	whereas	decreased	CstF64	
levels	 reduce	 efficiency	 of	 proximal	 PAS	 recognition,	 which	 allows	 the	 stronger	more	
distal	PAS	site	to	be	recognized	by	the	3’	end	processing	machinery	(refer	to	Figure	1-G.)	
(Yao	et	al.	2012).	This	is	similar	to	the	APA	pattern	observed	for	Fip1	KD.	Shifting	the	APA	
pattern	to	distal	PAS	usage	during	stem	cell	differentiation	and	development	leads	to	a	
decrease	 in	 the	 mRNA	 levels	 of	 many	 core	 3’	 processing	 factors,	 including	
CstF64/τ(Shepard	 et	 al.	 2011;	 Ji	 et	 al.	 2009;	 Ji	 and	 Tian	 2009).	 iCLIP-seq	 and	 in	 vitro	
biochemical	 data	 reveal	 that	 the	 strength	of	 interaction	between	CstF64	and	PASs	on	
mRNA	vary	greatly.	Research	has	shown	that	the	RNA-binding	specificities	of	CstF64	and	
its	paralog	CstF64τ	overlap	one	another.	Thus,	the	factors	may	play	redundant	roles	in	
APA	regulation.	This	functional	redundancy	likely	explains	why	depletion	of	CstF64	alone	
had	 a	 minor	 effect	 on	 cellular	 growth	 and	 the	 APA	 profile	 compared	 to	 when	 both	
CstF64/τ	were	co-depleted(Yao	et	al.	2012).		
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RT-q	 PCR	 data	 verifying	 APA	 changes	 in	 six	 genes.	 Increased	 levels	 of	 CSTF64	
promote	proximal	PAS	usage	whereas	decreased	CstF64	levels	reduce	efficiency	of	
proximal	PAS	recognition.	Thus	the	stronger	more	distal	PAS	site	is	recognized	by	the	
3’	end	processing	machinery	y-axis	 shows	 the	 log2	 ratio	of	 RNAi/HeLa	 (extended/	
common).	Adapted	from	Yao	et	al.	(2012)	
	
Figure	1-F:	KD	of	CstF64	results	in	APA	Changes	in	six	target	genes	
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Histone	mRNA	3’-end	Processing:	
	
Maturation	of	histone	pre-mRNAs,	which	are	not	polyadenylated,	requires	only	a	
single	cleavage	event	between	an	upstream	stem	loop	(SL)	analogous	to	the	AAUAAA	in	
canonical	poly(A)	mRNAs,	and	the	histone	downstream	element	(HDE)	(Figure	1-G).	The	
SL	 in	histone	mRNAs	 is	bound	by	the	stem	 loop	binding	protein	 (SLBP),	while	 the	HDE	
interacts	with	the	U7	RNA	component	of	the	U7	small	nuclear	ribonucleic	protein	particle	
(snRNP)	(Marzluff	et	al.	2008).	Histone	mRNA	processing	factors	are	recruited	to	the	pre-
mRNA’s	3’-end	via	the	U7snRNP	due	to	an	interaction	between	Lsm11	and	FLASH	(Sabath	
et	al.	2013).	While	both	types	of	mRNAs	use	unique	proteins,	an	essential	core	cleavage	
complex	comprised	of	CPSF73,	CPSF100,	and	Symplekin	is	required	for	proper	processing	
of	all	metazoan	mRNAs	(Figure	1-H).	CPSF73	is	the	endonuclease	performing	the	cleavage	
reaction	 (Mandel	 et	 al.	 2006),	 CPSF100	 binds	 to	 CPF73	 forming	 a	 heterodimer,	 and	
Symplekin	acts	as	a	scaffolding	protein	onto	which	the	other	two	proteins	bind	(Dominski	
et	al.	2005;	Takagaki	and	Manley	2000).	
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Figure	1-G:	Histone	pre-mRNA	3’-end	processing.	
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Schematic	of	Canonical	Histone	pre-RNA	mRNA	3’-end	Processing.	Unlike	canonical	
poly(A)	mRNAs,	histone	mRNAs	end	 in	a	highly	conserved	stem	loop	(SL)	~5	bases	
upstream	of	the	cleavage	site.	10	nucleotides	downstream	of	the	cleavage	site	lies	
the	 less	 conserved	 histone	 downstream	 element	 (HDE).	 Following	 cleavage,	 the	
upstream	 cleavage	 element	 represents	 the	 mature	 histone	 mRNA	 while	 the	
downstream	cleavage	element	is	degraded	to	single	nucleotides.	
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Previous	 in	vivo	 studies	 in	Drosophila	Dmel-2	cells	have	demonstrated	that	 the	
mRNA	3’-end	processing	factors	Symplekin,	CPSF73,	and	CPSF100	(here	termed	the	Core	
Cleavage	Cpmplex	or	CCC)	 form	a	stable	complex	vital	 for	proper	3’-end	processing	of	
both	histone	and	canonical	poly(A)	pre-mRNAs.	RNAi-mediated	knock-down	of	individual	
CCC	proteins	 results	 in	 co-depletion	of	 the	other	 two	 factors,	 indicating	 tight	 complex	
formation	between	these	proteins	(Figure	1-I).	In	addition,	knock-down	of	individual	CCC	
proteins	 leads	 to	misprocessing	 of	 histone	 pre-mRNAs	 (Figures	 1-J).	Misprocessing	 of	
Drosophila	histone	mRNAs	results	in	one	of	two	outcomes	depending	on	the	processing	
factor	involved.	In	the	Drosophila	genome,	the	3’-	ends	of	four	histone	genes	are	less	than	
500	nucleotides	from	the	3’-end	of	an	adjacent	gene	transcribed	from	the	opposite	strand	
(Figure	1-K).	The	close	proximity	of	the	histone	genes	on	Drosophila	chromosome	2	makes	
it	essential	to	efficiently	terminate	transcription	at	the	proper	histone	processing	site	so	
that	read-through	(RT)	transcription	does	not	occur	into	the	adjacent	gene.	Thus,	several	
cryptic	polyadenylation	signals	exist	downstream	of	each	Drosophila	histone	gene	incase	
processing	efficiency	of	histone	mRNAs	is	reduced	(mutation	or	knock-down	of	protein	
factors	required	for	histone	mRNA	3’-end	processing).	In	such	a	case	where	histone	mRNA	
processing	 efficiency	 is	 reduced,	 RNA	 Polymerase	 II	 will	 read-through	 to	 the	 cryptic	
poly(A)	sites,	and	the	mRNAs	will	become	polyadenylated	(Figures	1-J,	1-K,	&1-L)	(Godfrey	
et	al.,	2006;	Sullivan	et	al.,	2001).	If	the	proper	histone	processing	site	is	not	recognized	
the	cryptic	poly(A)	sites	can	be	utilized	by	the	poly(A)	3’-end	processing	machinery	and	
generate	 poly(A)	 histone	 mRNAs,	 but	 only	 if	 the	 poly(A)	 specific	 3’-end	 processing	
machinery,	which	includes	the	CCC,	is	intact	(Figure	1-L)	(Sullivan	et	al.	2009;	Godfrey	et	
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al.	 2006).	 If	 a	 poly(A)	 3’-end	 processing	 factor	 is	 RNAi-depleted	 a	 read-through	 (RT)	
transcript	bypassing	all	cryptic	poly(A)	signals	is	generated.	This	is	presumably	due	to	the	
inability	 of	 the	 poly(A)	 3’-end	 processing	 machinery	 to	 recognize	 and	 cleave	 at	 the	
downstream	cryptic	poly(A)	sites	(Figures	1-J	&	1-L).	These	preliminary	data	highlight	the	
importance	of	the	CCC	in	proper	3’-end	processing	of	all	metazoan	pre-mRNAs.		
RNA-processing	reactions	do	not	occur	as	individual	events,	but	instead	have	been	
shown	 to	 occur	 cotranscriptionally	 (reviewed	 in	 Bentley,	 2005;	 Buratowski,	 2005;	
Neugebauer,	 2002;	 Proudfoot,	 2004).	 Several	 components	 of	 the	 poly(A)	 mRNA	
processing	 apparatus	 directly	 bind	 the	 Carboxy-terminal	 domain	 (CTD)	 of	 RNA	 Pol	 II	
(Kyburz	et	al.,	2003;	McCracken	et	al.,	1997;	Phatnani	and	Greenleaf,	2004),	implying	that	
numerous	cleavage	and	polyadenylation	factors	can	be	loaded	onto	RNA	polymerase	II.	
Several	cleavage	and	polyadenylation	factors	have	been	found	to	associate	with	genes	
encoding	mRNAs	via	the	use	of	chromatin	immunoprecipitation	(ChIP)	experiments,	and	
in	 vitro	 experiments	 have	 shown	 the	 CTD	 to	 be	 important	 for	 efficient	 cleavage	 and	
polyadenylation	reactions	to	occur	(Hirose	and	Manley,	1998).	Lastly,	in	vitro	data	shows	
that	Drosophila	RNA	Pol	II	pauses	just	3’	of	the	proper	histone	mRNA	processing	site	on	
histone	genes.	This	pausing	potentially	positions	RNA	Pol	II	in	a	position	that	allows	for	
cotranscriptional	 assembly	 of	 the	 processing	 complex	 (Adamson	 and	 Price,	 2003).	
Collectively	 these	 data	 support	 the	 idea	 that	 the	 3’-ends	 of	 both	 polyadenylated	 and	
histone	mRNAs	are	formed	cotranscriptionally.	
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Figure	1-H:	Schematic	illustration	of	the	3	CCC	proteins	
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Schematic	illustration	of	the	Core	Cleavage	Complex	factor	proteins:	Symplekin	
(top),	 CPSF73	 (middle),	 and	 CPSF100	 (bottom).	 Biologically	 important	 protein	
domains	 are	 labeled	 as	 shaded	 boxes	 within	 the	 schematic	 for	 each	 protein.	
CPSF73	 is	 the	endonuclease	 that	 carries	out	 the	mRNA	cleavage	 reaction,	and	
catalytically	important	residues	are	listed	above	the	schematic	for	that	protein.	
Adapted	from	Michalski	and	Steiniger,	(2015)	
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Figure	1-I:	Co-depletion	of	Core	Cleavage	Complex	proteins		
	
	
Co-depletion	of	Core	 Cleavage	Complex	 factors.	 Target	proteins	were	 individually	
depleted	via	RNAi,	which	requires	the	addition	of	dsRNA	complementary	to	the	open	
reading	frame	(ORF)	of	the	corresponding	protein.	Next	Nuclear	extracts	(NE)	were	
prepared.	SDS-PAGE	and	Western	blotting	was	used	to	resolve		15ug	of	NE	using	the	
indicated	antibodies.	“Loading	control”	is	a	cross-reacting	band	from	the	Symplekin	
antibody	on	the	blot.	KD	of	one	core	cleavage	complex	factor	via	RNAi	results	in	co-
depletion	of	the	other	two	factors.	This	suggests	tight	complex	formation	between	
the	three	protein	factors.	Adapted	from	Sullivan	et	al.	(2009)	
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Figure	1-J:	KD	of	pre-mRNA	3’-end	processing	factors	results	in	histone	mRNA	
misprocessing	
	
			
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Knockdown	of	pre-mRNA-processing	factors	results	in	misprocessed	histone	mRNA.	
Dmel-2	cells	were	treated	with	target	dsRNAs,	and	total	RNA	was	prepared.	12.5	μg	
total	 RNA	was	 analyzed	 by	 S1	 nuclease	 protection	 assay.	Diagrams	 at	 left	 indicate	
dsRNA	species	corresponding	to	protected	fragments.	Undigested	probe	is	shown	in	
lane	 13	 for	 reference.	 Read-through	 transcripts	 (RT)	 are	 marked	 with	 an	 arrow.	
Adapted	from	Sullivan	et	al.,	(2009).	
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Figure	1-K:	Schematic	of	Drosophila	histone	gene	locus	
	
	
	
	
	
	
	
	
	
	
	
	
	
257nt
Schematic	 of	 one	 repeat	 (~5	 kb)	 within	 the	 Drosophila	 histone	 gene	 locus.	 The	
direction	of	transcription	 is	shown	directly	below	each	histone	gene	(H1,	H2A,	H2B,	
H3,	and	H4).	The	number	of	nucleotides	between	each	histone	gene	is	shown	above.	
Adapted	from	Michalski	and	Steiniger,	(2015).	
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Figure	1-L:	Misprocessed	histone	mRNAs	are	polyadenylated	following	KD	of	histone	
specific	processing	factors:		
	
	
	
	
	
	
	
	
	
	
		
	
Knockdown	of	Pre-mRNA-Processing	Factors	Results	in	Misprocessed	Histone	mRNA.	
25ug	total	RNA	was	fractionated	on	oligo(dT)	cellulose,	and	the	purified	poly(A)+	RNA	
was	used	for	running	S1	nuclease	protection	assay.	A	small	amount	of	processed	histone	
mRNA	 nonspecifically	 binds	 to	 the	 oligo(dT)	 cellulose.	 Adapted	 from	 Sullivan	 et	 al.	
(2009).		
	 																																																																																																												Michalski,	Daniel,	UMSL			
	
41	
U7snRNA	and	the	U7snRNP:	
	
	 The	U7snRNA	is	approximately	58–63	nucleotides	long,	depending	on	the	species,	
and	is	bound	by	a	number	of	Sm	and	Sm-like	(Lsm)	proteins.	These	Sm	and	LSM	proteins	
are	characterized	by	two	closely	spaced,	conserved	Sm	motifs	 (1	and	2)	 (Cooper	et	al.	
1995;	Hermann	et	 al.	 1995;	 Séraphin	 1995),	 and	 adopt	 a	 fold	 consisting	 of	 an	α-helix	
followed	 by	 five	 β-strands(Kambach	 et	 al.	 1999).	 A	 common	 characteristic	 of	 Sm/Lsm	
proteins	is	their	tendency	to	form	oligomers	that	can	close	into	hepta-	or	hexameric	ring	
structures.	 These	 structures	 control	 and/or	 contribute	 to	 various	 aspects	 of	 RNA	
metabolism	(Pillai	et	al.	2001).	The	seven	prototype	Sm	proteins	B/B’,	D1,	D2,	D3,	E,	F,	
and	 G	 form	 the	 Sm	 core	 structure	 around	 the	 conserved	 Sm-binding	 site	 of	 the	
spliceosomal	small	nuclear	RNAs	(Pillai	et	al.	2003).	The	U7snRNP	contains	a	unique	Sm-
binding	 site	 thought	 to	 be	 partially	 responsible	 for	 its	 unique	 Sm	 protein	
composition(Pillai	et	al.	2001).	The	5ʹ-end	of	the	U7snRNA	is	complementary	to	the	HDE	
in	 histone	 pre-mRNAs.	 Base-pairing	 between	 the	 U7snRNA	 and	 the	 HDE	 is	 vital	 for	
assembling	a	functional	histone	3’-end	processing	complex	(Müller	and	Schümperli	1997;	
Dominski	 and	Marzluff	 1999).	 Following	 this	 base-pairing	 region,	 U7snRNAs	 contain	 a	
non-canonical	Sm-binding	site,	AAUUUGUCUAG,	followed	by	a	long	hairpin	structure	and	
a	short	single-stranded	3ʹ	extension.		 	
Previous	 in	 vitro	 and	 in	 vivo	 studies	 identified	 LSM10	 and	 LSM11	 as	 U7snRNP	
specific	proteins	replacing	the	canonical	Sm	proteins	D1	and	D2	(Pillai	et	al.	2003).	The	Sm	
binding	site	of	the	U7snRNA	is	different	from	that	found	in	other	spliceosomal	snRNAs.	
This	unique	feature	of	the	U7snRNA	is	thought	to	be	responsible	for	the	relatively	 low	
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abundance	 of	 U7snRNPs	within	 the	 cell	 (Pillai	 et	 al.	 2001).	When	 the	 unique	 U7	 Sm-
binding	site	(AAUUUGUCUAG)	was	converted	to	the	consensus	sequence	of	spliceosomal	
snRNPs	 (AAUUUUUGGAG),	 the	 resulting	 snRNPs	 accumulated	 more	 efficiently	 into	
transfected	 cells	 or	 microinjected	 Xenopus	 oocytes,	 yet	 they	 were	 non-functional	 in	
histone	mRNA	3ʹ	processing	(Pillai	et	al.	2003).	This	finding	suggests	that	the	unique	U7	
Sm-binding	sequence	is	at	least	partially	responsible	for	assembling	the	U7-specific	snRNP	
structure,	whereas	the	canonical	Sm-binding	site	results	in	standard	Sm-core	structures	
(Pillai	et	al.	2001).	 	
The	 “survival	 of	 motor	 neurons”	 (SMN)	 protein,	 which	 is	 a	 part	 of	 the	 SMN	
complex,	is	a	key	player	in	Sm	ring	formation.	This	complex	is	composed	of	18	or	more	
distinct	 proteins,	 including	 all	 of	 the	 Sm	 proteins(Meister	 et	 al.	 2001;	 Pellizzoni	 et	 al.	
2002).	 In	 vitro	 reconstitution	of	 the	 assembly	 reaction	 revealed	 that	 Sm	proteins	 first	
associate	with	the	SMN	complex	in	the	cytoplasm	and	are	subsequently	transferred	to	
the	U	snRNA	and	shuttled	to	the	Histone	Locus	Body	(HLB)	within	the	nucleus	(Pillai	et	al.	
2003).	Additional	studies	have	shown	that	the	SMN	complex	mediating	spliceosomal	U	
snRNP	assembly	 is	not	 the	 same	complex	mediating	U7snRNP	assembly.	A	 specialized	
SMN	complex	 that	 lacks	 Sm	proteins	D1	and	D2	but	 contains	 the	U7-specific	proteins	
Lsm10	and	Lsm11	facilitates	U7snRNP	formation(Pillai	et	al.	2003).		
Thus,	 current	 data	 suggest	 that	 assembly	 and	 subsequent	 function	of	 the	U7snRNP	 is	
specified	by	its	unique	set	of	Sm/Lsm	proteins	and	its	unique	Sm-binding	site	(Pillai	et	al.	
2003).	Experimental	in	vitro	data	reveals	that	the	N-terminal	portion	of	LSM11	contacts	
FLASH	 (a	 histone	 specific	 processing	 factor),	 and	 that	 this	 interaction	 is	 essential	 for	
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proper	histone	mRNA	3’-end	formation	(Figure	1-M)	(Sabath	et	al.	2013).	In	vitro	studies	
in	Drosophila	reveal	that	the	N-terminal	region	of	LSM11	(a.a.1-78)	contacts	an	internal	
region	 of	 the	 histone	 specific	 processing	 factor	 FLASH	 (a.a.105-154),	 and	 that	 this	
interaction	 is	 required	 for	 proper	 histone	mRNA	 3’-end	 formation.	 The	 same	 studies	
suggest	 that	 the	 last	 45	 amino	 acids	 of	 the	 FLASH	 protein	 are	 required	 for	 efficient	
localization	of	the	U7snRNP	to	the	HLB	within	the	nucleus,	and	that	amino	acid	residues	
64-77	of	FLASH	 interact	with	a	yet	unknown	factor	 that	 is	 required	 for	proper	histone	
mRNA	processing.	The	first	64	amino	acids	of	FLASH	were	found	to	be	dispensable	for	
both	U7snRNP	localization	to	the	HLB	and	histone	mRNA	3’-end	processing.	In	addition,	
exogenous	expression	of	HA-tagged	LSM11	mutants	 in	human	293T	cells	revealed	that	
the	C-terminal	region	of	LSM11	contains	the	Sm	domain,	which	consists	of	the	two	Sm-
binding	motifs(Pillai	et	al.	2003).	This	C-terminal	region	is	suggested	to	be	sufficient	for	
snRNP	assembly	in	general,	but	also	carries	the	specificity	for	preferential	association	with	
the	 U7snRNA	 (Pillai	 et	 al.	 2003).	 The	 genome	 of	 the	 model	 organism	 Drosophila	
melanogaster	possesses	100	tandem	copies	of	a	5	kb	repeat	region	containing	a	single	
copy	of	each	histone	gene	(H2A,	H2B,	H3,	H4,	and	H1)	on	the	long	arm	of	chromosome	2	
(Figure	1-K).	This	repeat	region	of	histone	genes	cluster	together	and	localizes	to	nuclear	
structures	termed	histone	 locus	bodies	 (HLBs),	which	are	 located	 in	close	proximity	 to	
Cajal	bodies	(CBs)	(Liu	et	al.,	2006).	HLBs	also	contain	U7	snRNPs,	the	CCC	factor	Symplekin	
(Wagner	et	al.,	2007),	and	Mpm-2	(White	et	al.,	2007),	providing	evidence	for	a	role	for	
these	nuclear	bodies	in	histone	mRNA	biosynthesis.		
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Schematic	illustration	of	the	U7snRNP	particle	interacting	with	the	3’-end	cis	elements	
of	histone	pre-mRNAs.	Base	pairing	between	the	5’-end	of	the	U7snRNA	molecule	and	
the	 HDE	 is	 required	 for	 proper	 histone	 mRNA	 3’-end	 processing.	 Also	 drawn	 are	
additional	 3’-end	 processing	 factors	 known	 to	 be	 involved	 in	 histone	 pre-mRNA	
processing	in	Drosophila.	Adapted	from	Sabath	et	al.	(2014).		
 
Figure	1-M:	U7snRNP	particle	interacts	with	the	3’-end	cis	elements	(HDE)	of	histone		
pre-mRNAs	
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Figure	1-N:	U7snRNP	interacts	w/	the	CCC	and	other	Histone	specific	factors	
	
	
	
Schematic	illustrating	potential	interactions	of	the	U7snRNP	with	the	CCC	
and	 other	 polyadenylation	 factors.	 Here	 Flash	 binding	 to	 the	 U7snRNP	
creates	 a	 “primed”	U7snRNAP	 capable	 of	 interacting	with/recruiting	 the	
essential	 CCC	 factors	 (CPSF73,	 CPSF100,	 Symplekin).	 This	 complex	 then	
recruits	other	processing	factors	necessary	for	proper	histone	mRNA	3’-end	
processing.		Image	Adapted	from	Sabath	et	al.	(2014).	
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Core	 Cleavage	 Complex:	 Interaction	 between	 Symplekin,	 CPSF73,	 and	 CPSF100	 form	 a	
tightly	bound	complex	responsible	for	all	pre-mRNA	processing:	
	
Cleavage	 and	 polyadenylation	 of	 all	 metazoan	 poly(A)	 mRNAs	 requires	 the	
presence	of	 two	multiprotein	 complexes:	 the	 cleavage	 and	polyadenylation	 specificity	
factor	 (CPSF)	 complex	 and	 the	 cleavage	 stimulation	 factor	 (CstF)	 complex,	 which	
recognize	 cis	 element	 signals	 upstream	 and	 downstream	 of	 the	 cleavage	 site,	
respectively.	CPSF	is	composed	of	at	least	CPSF30,	CPSF73,	CPSF100,	and	CPSF160,	which	
interact	 with	 one	 another	 (reviewed	 in	 Mandel	 et	 al.,	 2008)	 and	 with	 the	 AAUAAA	
polyadenylation	 signal	 that	 is	 recognized	 by	 CPSF30	 and	WDR33	 (Schönemann	 et	 al.	
2014).	 Prior	 to	 2014	 CPSF160	 was	 thought	 to	 be	 the	 protein	 responsible	 for	 directly	
contacting	 the	 AAUAAA	 polyadenylation	 signal	 within	 the	 mRNA	 (Keller	 et	 al.,	 1991;	
Murthy	 and	 Manley,	 1995).	 CPSF73	 and	 CPSF100	 are	 similar	 both	 in	 sequence	 and	
structural	domain	organization.		CPSF73	and	CPSF100	both	have	putative	Beta-lactamase	
domains,	 but	while	 CPSF73	 has	 been	 described	 as	 the	 endonuclease	 for	 both	 poly(A)	
(Mandel	 et	 al.,	 2006)	 and	 histone	 mRNAs	 3’-end	 processing	 (Dominski	 et	 al.	 2005),	
CPSF100	 lacks	the	critical	 residues	required	for	catalysis	and	thus	displays	no	nuclease	
activity	(Figure	1-H).	CPSF100	has	been	shown,	however,	to	play	an	important	role	in	the	
cleavage	reaction	(Kolev	et	al.,	2008).	CstF64,	a	member	of	the	CstF	complex,	binds	the	
downstream	 U-/GU-rich	 element	 required	 for	 polyadenylation	 (Yoshio	 and	 Manley,	
1997).	The	CCC	factor	Symplekin,	which	was	originally	identified	as	a	tight	junction	protein	
in	 mammalian	 cells	 (Keon	 et	 al.,	 1996),	 and	 its	 yeast	 homolog,	 Pta1p,	 was	 initially	
characterized	as	being	essential	for	pre-tRNA	processing	(O’Connor	and	Peebles,	1992),	
has	been	shown	to	interact	with	both	CPSF	and	CstF	in	yeast	(Preker	et	al.,	1997;	Zhao	et	
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al.,	 1999)	 and	 mammals	 (Takagaki	 and	 Manley,	 2000;	 Vethantham	 et	 al.,	 2007).	 In	
addition,	Symplekin	was	defined	as	the	heat-labile	factor	(Gick	et	al.,	1987)	required	for	
histone	pre-mRNA	3’-end	processing	(Kolev	and	Steitz,	2005).	
	Together,	 CPSF73,	 CPSF100,	 and	 Symplekin	 form	 the	 so	 called	 Core	 Cleavage	
Complex,	or	CCC.	Details	describing	CPSF73,	CPSF100	and	Symplekin	interactions	are	not	
available	as	no	 structural	data	 corresponding	 to	 the	Core	Cleavage	Complex	has	been	
published	 and	 X-ray	 crystal	 structures	 of	 individual	 components	 are	 limited.	 Each	
individual	core	cleavage	complex	protein	has	X-ray	crystal	structures	representing	some	
portion	of	the	complete	protein,	but	X-ray	crystal	structural	data	for	complete	proteins	
individually	or	 in	 complex	with	one	another	 is	missing	 for	 the	 core	 cleavage	 complex.	
Figure	1-O	reveals	the	crystal	structure	of	the	~N-terminal	2/3	of	both	human	CPSF73	and	
yeast	CPSF100,	which	includes	the	two	major	domains	of	each	protein	(beta-CASP	domain	
and	metallo-beta-lactamase	domain).	Present	 in	the	human	CPSF73	crystal	structure	is	
the	theoretical	active	site	with	the	pair	of	zinc	ions	required	for	enzymatic	activity.	Both	
crystal	 structures	 are	displayed	 showing	 the	 alpha-helices	 and	beta-sheets.	 Figure	 1-P	
provides	a	closer	 look	at	the	beta-CASP	domain	of	both	proteins,	while	Figure	1-Q	is	a	
stick	model	of	the	active	site	within	CPSF73.	Figure	1-R	is	a	secondary	structural	view	of	
the	N-terminal	271	a.a.	of	Symplekin,	which	were	found	to	comprise	a	HEAT	domain.	The	
alpha-helices	create	the	convex	face	of	the	HEAT	domain,	while	the	beta-helices	create	
the	concave	face.	HEAT	domains	are	notorious	protein	binding	sites,	thus	giving	rise	to	
the	notion	that	Symplekin	is	likely	a	scaffolding	protein.		
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Figure	1-O:	Crystal	Structures	for	partial	proteins	of	CPSF73	and	CPSF100	
	
	
	
	
	
Structures	 of	 human	 CPSF-73	 and	 yeast	 CPSF-100	 (Ydh1).	 a,	 Schematic	
representation	of	the	structure	of	human	CPSF-73.	Secondary	structures	(b-strands	
and	a-helices)	are	labelled.	The	two	zinc	atoms	in	the	active	site	are	shown	as	grey	
spheres.	The	sulphate	ion	is	shown	as	a	stick	model.	b,	Schematic	representation	of	
the	structure	of	yeast	CPSF-100.	Zinc	atoms	in	the	CPSF-73	structure	are	shown	for	
reference.	See	Figure	1-H	for	schematic	drawings	of	the	metallo-b-lactamase	domains	
of	CPSF73	and	CPSF100.	Adapted	from	Corey	R.	Mandel	et	at.,	(2006)		
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Figure	1-P.	The	b-CASP	domain	of	CPSF-73	and	CPSF-100:	
	
	
Schematic	representation	of	the	b-CASP	domains	of	human	CPSF-73	 (a)	
and	yeast	CPSF-100	(b).	Secondary	structures	(b-strands	and	a-helices)	are	
labelled.	Adapted	from	Corey	R.	Mandel	et	al.,	(2006)	
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Figure	1-Q:	CPSF73	Active	Site	
 
The	active	site	of	CPSF-73:Stick	model	representing	the	CPSF73	active	site	a)	Shows	
the	 Zinc	 binding	 site	 for	 human	 CPSF-73,	 with	 motifs	 labelled,	 and	 the	 bridging	
hydroxide	 ion	 shown	as	a	 red	 sphere.	 Liganding	 interactions	are	 indicated	by	 thin	
magenta	 lines,	 and	 hydrogen-bonding	 interactions	 by	 thin	 red	 lines.	 The	 arrow	
represents	the	nucleophilic	attack	from	the	hydroxide	ion.	B)	Shows	the	Zinc	binding	
site	in	L1	metallo-b-lactamase.	Adapted	from	Corey	R.	Mandel	et	al.,	(2006).	
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Figure	1-R:	Symplekin	Heat	Domain	Crystal	Structure	
	
	
	
	
	
	
	
Symplekin	 HEAT	 domain	 structure.	 (a)	 stereo	 view	 representation	 the	 original	
experimental	electron	density.	(b)	Structural	view	of	the	HEAT	domain	within	the	N-
terminal	271	a.a.	of	Symplekin.	Alpha	helices	are	lettered	and	numbered	according	to	
classical	HEAT	naming;	the	alpha-helices	create	the	convex	face,	while	the	beta-helices	
create	the	concave	face.	The	rainbow	denotes	the	N	to	C	progression	of	residues	22–	
270.	(c)	Stick	model	indicating	polar	contacts	within	the	loop	8	region	of	Symplekin.	A.	
Kennedy	et	al.,	(2009)	
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Prior	 to	 this	 dissertation	 study,	 researchers	 investigating	 the	 role	 of	 CPSF73,	
CPSF100,	 and	 Symplekin	 in	 histone	 and	 poly(A)	 pre-mRNA	 processing	 found	 that	
Symplekin,	CPSF73,	and	CPSF100	form	a	tightly	bound	complex,	here	termed	the	“Core	
Cleavage	 Complex,”	 that	 is	 essential	 for	 proper	 cotranscriptional	 3’-end	 pre-mRNA	
processing	of	all	metazoan	mRNAs	(Figures	1-I,	1-J,	1-L).	The	outcome	of	cleavage	and	
polyadenylation	 of	 histone	 and	 poly(A)	 mRNAs	 is	 known,	 yet	 many	 of	 the	 molecular	
details	regarding	the	protein-protein	and	protein-mRNA	interactions	that	must	occur	for	
proper	3’-end	mRNA	processing	are	unknown.	Since	the	Core	Cleavage	Complex	plays	an	
integral	 role	 in	 the	 3’-end	 processing	 of	 all	 metazoan	 pre-mRNAs	 (2009),	 I	 feel	 that	
determining	the	biologically	relevant	binding	interactions	in	this	complex	is	important,	as	
it	will	provide	vital	structural	details	in	a	complex	vital	for	proper	gene	regulation	at	the	
post-transcriptional	level.	In	addition,	determining	the	functionality	of	mutant	CCCs	will	
further	elucidate	each	factors	role	in	histone	mRNA	3’-end	formation.	 
This	current	study,	described	in	detail	in	this	dissertation	document,	builds	upon	
the	 foundation	 set	 by	 the	 previous	 study	 that	 described	 the	 existence,	 role,	 and	
importance	 of	 the	 core	 cleavage	 complex	 in	 the	 process	 of	 proper	 3’-end	 mRNA	
formation.	This	current	study	aims	to	both	characterize	the	minimal	regions	of	each	core	
cleavage	complex	factor	protein	required	for	binding	to	its	endogenous	binding	partners	
and	thus	still	allow	complex	formation	to	occur,	and	then	to	subsequently	examine	the	
functionality	of	mutant	CCCs	on	histone	pre-mRNA	processing.	The	aims	of	this	study	will	
further	elucidate	the	molecular	interactions	between	the	CCC	proteins	and	subsequently	
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determine	whether	the	minimal	protein	regions	required	for	complex	formation	still	allow	
for	efficient	proper	3’-end	mRNA	processing	of	histone	genes	in	Drosophila	melanogaster.	 
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CHAPTER	2:	General	Methodology	and	Materials	
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Plasmids	and	Oligonucleotides	Used	in	this	Study	
	
All	oligonucleotides	used	 in	 this	 study	 for	 the	amplification	of	Core	Cleavage	Complex	
genes	or	gene	regions	(mutant	proteins)	and	for	sequencing	are	listed	in	Table	2-A.	All	
entry	plasmids	generated	in	this	study	for	downstream	applications	(recombination	into	
destination	vectors)	are	listed	in	Table	2-B.	All	destination	plasmids	generated	from	the	
entry	 vector	 and	 subsequently	 transfected	 into	Dmel-2	 cells	 in	 this	 study	 are	 listed	 in	
Table	2-C.		
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Table	2-A.	Oligonucleotides	used	in	this	Study	(Amplification	of	Gene	Regions	and	
Sequencing)	
					Oligo	Name		 									Gene	Region	 							Nucleotide	Sequence	(5'	-->	3')	
M13	Forward	(-20)	 Vector	(pENTR/D	Topo®)	 GTAAAACGACGGCCAGT	
M13	Reverse	(-27)	 Vector	(pENTR/D	Topo®)	 CAGGAAACAGCTATGAC	
PENTR	CPSF73	N-
terminal	
CPSF73	(1)	F	 CACCATGACGCAGGCAACAGGTGAT	
PENTR	CPSF73	C-
terminal	
CPSF73	(684)	R	 TCAAAGAGCGGAGACTAGGGT	
73(466-684)	stop	F	 CPSF73	(466-684)	F		 CCTAGTCTCCGCTCTTTAGGGTGGGCGCGCC	
73(466-684)	stop	R	 CPSF73	(466-684)	R		 GGCGCGCCCACCCTAAAGAGCGGAGACTAGG	
73	(1-465)	stop	F	 CPSF73	(1-465)	F	 GGATCTTTATTTCCGTTAGGGTGGGCGCGCC	
73	(1-465)	stop	R	 CPSF73	(1-465)	R		 GGCGCGCCCACCCTAACGGAAATAAAGATCC	
Symp	FL	+	(272-1165)	
stop	F	
Symplekin	(272-1165)	F	 CCGCCTGGCGAGGACTAGGGTGGGCGCGCC	
Symp	FL	+	(272-1165)	
stop	R	
Symplekin	(272-1165)	R		 GGCGCGCCCACCCTAGTCCTCGCCAGGCGG	
Symp	(1-271)	stop	F	 Symplekin	(1-271)	F	 GGAAGCCTTTAAGCAGTAGGGTGGGCGCGCC	
Symp	(1-271)	stop	R	 Symp	(1-271)	R		 GGCGCGCCCACCCTACTGCTTAAAGGCTTCC	
100	FL	stop	F	 CPSF100	(1)	F	 CAGTATGCGATCGTTTAGGGTGGGCGCGCC	
100	FL	stop	R	 CPSF100	(758)	R	 GGCGCGCCCACCCTAAACGATCGCATACTG	
100	(1-524)	stop	F	 CPSF100	(1)	F	 CGTCGACAATGATGTTTAGGGTGGGCGCGCC	
100	(1-524)	stop	R	 CPSF100	(524)	R		 GGCGCGCCCACCCTAAACATCATTGTCGACG	
100	(525-758)	start	F	 CPSF100	(525)	F	 GCCGCCCCCTTCACCATGCAGTTGCTGGAGAAGCCC	
100	(525-758)	start	R	 CPSF100	(758)	R	 GGGCTTCTCCAGACCCTGCATGGTGAAGGGGGCGGC	
T7	RNA	Pol	Binding	
Sauce	
Vector	 ggtaatacgactcactataggg	
T7	Promoter	 Vector	 TAATACGACTCACTATAGGG	
T7	Terminator	 Vector	 GCTAGTTATTGCTCAGCGG	
GFP-C	 GFP	 CATGGTCCTGCTGGAGTTCGTG	
GFP-N	 GFP	 CGTCGCCGTCCAGCTCGACCAG	
GFP-F	 GFP	dsRNA	target	region	 ggtaatacgactcactatagggcgtaaacggccacaagttca	
GFP-R	 GFP	dsRNA	target	region	 ggtaatacgactcactatagggttctcgttggggtctttgct	
CPSF73	dsRNA	R	 CPSF73	dsRNA	target	region	 TTCTGGATGAATTCTGGTCG	
CPSF73	dsRNA	S	 CPSF73	dsRNA	target	region	 ATGCGTTGGCTTTAGTAGG	
CPSF100	dsRNA	R	 CPSF100	dsRNA	target	region	 GAAGGCTTTCGAAGGTGC	
CPSF100	dsRNA	S	 CPSF100	dsRNA	target	region	 TAGGGGAACATCACGTGGT	
Symplekin	dsRNA	R	 Symplekin	dsRNA	target	region	 CGAGCTAATTTCCGTTCTGC	
M13	Forward	(-20)	 Vector	(pENTR/D	Topo®)	 GTAAAACGACGGCCAGT	
M13	Reverse	(-27)	 Vector	(pENTR/D	Topo®)	 CAGGAAACAGCTATGAC	
PENTR	CPSF73	N-
terminal	
CPSF73	(1)	F	 CACCATGACGCAGGCAACAGGTGAT	
PENTR	CPSF73	C-
terminal	
CPSF73	(684)	R	 TCAAAGAGCGGAGACTAGGGT	
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73(466-684)	stop	F	 CPSF73	(466-684)	F		 CCTAGTCTCCGCTCTTTAGGGTGGGCGCGCC	
73(466-684)	stop	R	 CPSF73	(466-684)	R		 GGCGCGCCCACCCTAAAGAGCGGAGACTAGG	
74	(1-465)	stop	F	 CPSF73	(1-465)	F	 GGATCTTTATTTCCGTTAGGGTGGGCGCGCC	
74	(1-465)	stop	R	 CPSF73	(1-465)	R		 GGCGCGCCCACCCTAACGGAAATAAAGATCC	
Symp	FL	+	(272-1165)	
stop	F	
Symplekin	(272-1165)	F	 CCGCCTGGCGAGGACTAGGGTGGGCGCGCC	
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Table	2-B.	Entry	plasmids	containing	all	gene	regions	used	in	CCC	binding	study	
										Entry	Plasmids	 																		Description		
pENTR/D	Topo®	 FL-Symplekin	
pENTR/D	Topo®	 FL-Symplekin+RNAi-R	
pENTR/D	Topo®	 N-term	Symplekin	(1-271)	
pENTR/D	Topo®	 C-term	Symplekin	(272-1165)	
pENTR/D	Topo®	 C-term	Symplekin	(272-1080)	
pENTR/D	Topo®	 C-term	Symplekin	(272-926)	
pENTR/D	Topo®	 C-term	Symplekin	(272-758)	
pENTR/D	Topo®	 C-term	Symplekin	(272-625)	
pENTR/D	Topo®	 C-term	Symplekin	(272-525)	
pENTR/D	Topo®	 C-term	Symplekin	(272-395)	
pENTR/D	Topo®	 C-term	Symplekin+RNAi-R	(272-1165)	
pENTR/D	Topo®	 C-term	Symplekin+RNAi-R	(272-1080)	
pENTR/D	Topo®	 C-term	Symplekin+RNAi-R	(272-926)	
pENTR/D	Topo®	 C-term	Symplekin+RNAi-R	(272-758)	
pENTR/D	Topo®	 FL-CPSF100	
pENTR/D	Topo®	 FL-CPSF100+RNAi-R	
pENTR/D	Topo®	 N-term	CPSF100	(1-524)	
pENTR/D	Topo®	 C-term	CPSF100	(525-758)	
pENTR/D	Topo®	 C-term	CPSF100	(525-647)	
pENTR/D	Topo®	 FL-CPSF73	
pENTR/D	Topo®	 FL-CPSF73+RNAi-R	
pENTR/D	Topo®	 N-term	CPSF73	(1-465)	
pENTR/D	Topo®	 C-term	CPSF73	(466-684)	
pENTR/D	Topo®	 C-term	CPSF73	(466-552)	
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Table	2-C.	Destination	Plasmids	used	for	transfection	of	Dmel-2	cells	
										Destination	Plasmids	 															*Description	
pAHW	 FL-Symplekin	
pAHW	 FL-Symplekin+RNAi-R	
pAHW	 N-term	Symplekin	(1-271)	
pAHW	 C-term	Symplekin	(272-1165)	
pAHW	 C-term	Symplekin	(272-1080)	
pAHW	 C-term	Symplekin	(272-926)	
pAHW	 C-term	Symplekin	(272-758)	
pAHW	 C-term	Symplekin	(272-625)	
pAHW	 C-term	Symplekin	(272-525)	
pAHW	 C-term	Symplekin	(272-395)	
pAHW	 C-term	Symplekin+RNAi-R	(272-1165)	
pAHW	 C-term	Symplekin+RNAi-R	(272-1080)	
pAHW	 C-term	Symplekin+RNAi-R	(272-926)	
pAHW	 C-term	Symplekin+RNAi-R	(272-758)	
pAHW	 FL-CPSF100	
pAHW	 FL-CPSF100+RNAi-R	
pAHW	 N-term	CPSF100	(1-524)	
pAHW	 C-term	CPSF100	(525-758)	
pAHW	 C-term	CPSF100	(525-647)	
pAHW	 FL-CPSF73	
pAHW	 FL-CPSF73+RNAi-R	
pAHW	 N-term	CPSF73	(1-465)	
pAHW	 C-term	CPSF73	(466-684)	
pAHW	 C-term	CPSF73	(466-552)	
pAWH	 FL-Symplekin	
pAWH	 FL-Symplekin+RNAi-R	
pAWH	 N-term	Symplekin	(1-271)	
pAWH	 C-term	Symplekin	(272-1165)	
pAWH	 C-term	Symplekin	(272-1080)	
pAWH	 C-term	Symplekin	(272-926)	
pAWH	 C-term	Symplekin	(272-758)	
pAWH	 C-term	Symplekin	(272-625)	
pAWH	 C-term	Symplekin	(272-525)	
pAWH	 C-term	Symplekin	(272-395)	
pAWH	 C-term	Symplekin+RNAi-R	(272-1165)	
pAWH	 C-term	Symplekin+RNAi-R	(272-1080)	
pAWH	 C-term	Symplekin+RNAi-R	(272-926)	
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pAWH	 C-term	Symplekin+RNAi-R	(272-758)	
pAWH	 FL-CPSF100	
pAWH	 FL-CPSF100+RNAi-R	
pAWH	 N-term	CPSF100	(1-524)	
pAWH	 C-term	CPSF100	(525-758)	
pAWH	 C-term	CPSF100	(525-647)	
pAWH	 FL-CPSF73	
pAWH	 FL-CPSF73+RNAi-R	
pAWH	 N-term	CPSF73	(1-465)	
pAWH	 C-term	CPSF73	(466-684)	
pAWH	 C-term	CPSF73	(466-552)	
*HW	=	N-term	3x	HA-tag			*WH	=	C-term	3x	HA-tag	
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Development	 and	 validation	 of	 a	 Dmel-2	 expression	 system	 to	 study	 in	 vivo	 protein	
interactions	in	the	CCC:		
	
Gene	Cloning	and	Plasmid	Construction:	
	
Full-length	CPSF73,	CPSF100	and	Symplekin	were	PCR	amplified	from	Drosophila	
gene	collection	(DGC)	clones	(Open	Biosystems)	using	specific	primers	listed	in	Table	2-A.	
The	 amplified	 genes	 were	 directionally	 cloned	 into	 pENTRTM	 D-TOPO	 (Invitrogen)	 to	
create	CPSF73,	CPSF100	and	Symplekin::pENTRTMD-TOPO.	Use	of	the	pENTRTM	D-TOPO	
(Invitrogen)	vector	to	directional	insert	our	gene	of	interest	required	the	addition	of	the	
CACC	4	nucleotide	sequence	5’	of	the	first	nucleotide	in	the	primer	used	to	PCR	amplify	
the	selected	gene	or	gene	region.	Insertion	reactions	were	transformed	into	chemically	
competent	DH5-alpha	 cells	 and	plated	onto	 LB+Kanamycin	 agar	 plates.	 Colonies	were	
selected,	grown	in	5mL	selective	media,	and	column	mini-prepped.	Proper	gene	insertion	
was	 confirmed	 via	 restriction	 digest	 and	 Sanger	 sequencing.	 CPSF73,	 CPSF100	 and	
Symplekin::pENTRTMD-TOPO	were	each	recombined	with	pAHW	and	pAWH	destination	
vectors	 (Drosophila	 Gateway	 vector	 collection,	 Carnegie	 Institution	 for	 Science)	 using	
Clonase	II	(Life	Technologies).	Recombination	reactions	were	transformed	into	chemically	
competent	 DH5-alpha	 cells	 and	 plated	 on	 LB+Ampicillin	 agar	 plates.	 Colonies	 were	
selected,	 grown	 in	 5mL	 selective	 media,	 and	 column	 mini-prepped.	 Proper	 gene	
recombination	was	confirmed	via	restriction	digest	and	Sanger	sequencing.		
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Figure	2-A:	Schematic	illustration	of	cloning	scheme	from	Entry	to	Destination	Vector	
	
	
	
	
	
	
	
	
	
	
Schematic	 illustration	 of	 the	 entry	 vector	 (pENTR	 TM/D-Topoâ)	 used	 for	 initial	
cloning	 of	 full	 length	 and	 mutant	 CCC	 proteins.	 The	 entry	 vectors	 undergo	 a	
recombination	 reaction	via	 their	 LR	 recombination	 sites	 into	 the	destination	vector	
(pAHW/pAWH).	 The	 destination	 vector	 adds	 a	 3x	 HA-tag	 to	 either	 the	 N-terminal	
(pAHW)	or	the	C-terminal	(pAWH)	of	the	protein.	Once	the	protein	of	interest	has	been	
confirmed	in	the	destination	vector,	these	plasmids	are	transfected	into	Dmel-2	cells	
and	 stably	 integrated	 into	 the	 genome	 under	 the	 selective	 pressure	 of	 Blasticidin.	
Expression	of	tagged	mutant	CCC	proteins	was	confirmed	via	Western	blot	using	anti-
HA	antibody.	Stable	cell	 lines	 (SCLs)	were	created	for	each	mutant	CCC	protein	and	
subsequently	used	in	downstream	applications.	
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Deletion	Mutant	Design,	Synthesis,	and	Gateway	Cloning	to	create	Entry	Vectors:	
	
Deletion	mutants	for	each	of	the	three	CCC	proteins	were	cloned	into	pENTRTMD-
TOPO	(Invitrogen)	as	described	for	their	full-length	counterparts.	Each	deletion	mutant	
was	initially	amplified	from	their	corresponding	pENTRTMD-TOPO	full-length	protein	
coding	gene,	providing	the	necessary	CACC	to	the	5’-end	of	the	forward	primer.	
Successful	synthesis	of	pENTRTMD-TOPO	deletion	mutants	was	confirmed	via	restriction	
digest	and	anger	sequencing.		
Destination	Vectors	construction:	
	
All	pENTRTMD-TOPO	deletion	mutants	were	subsequently	recombined	into	both	
pAHW	and	pAWH	destination	vectors	(Drosophila	Gateway	vector	collection,	Carnegie	
Institution	for	Science)	using	Clonase	II	(Life	Technologies)	as	described	for	their	full-
length	counterparts.	
	
RNAi-Resistant	Protein	design	and	synthesis:	
	
RNAi-resistant	(RNAi-R)	Symplekin,	CPSF73,	and	CPSF100	were	designed	using	an	
online	tool	described	in	Schulz	et	al.	(Schulz	et	al.	2009).	This	tool	changes	wobble	bases	
within	a	targeted	area	while	also	being	sensitive	to	codon	bias	(specific	 for	Drosophila	
melanogaster).	The	~500bp	dsRNA	fragment	used	for	RNAi-induced	protein	knockdown	
experiments	targets	a	specific	region	of	the	gene’s	ORF.	Thus	creation	of	RNAi-resistant	
versions	of	core	cleavage	factor	proteins	involved	input	of	this	same	targeting	nucleotide	
sequence	into	the	online	tool.	The	program’s	output	nucleotide	sequence	was	identical	
in	 length	 to	 the	 input	 sequence	but	had	every	3rd	base	of	 the	 codon	within	 the	 input	
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sequence	changed	to	the	next	most	likely	codon	that	still	coded	for	the	same	initial	amino	
acid.	This	corresponded	to	~180	nucleotides	being	different/changed	from	the	initial	wild-
type	 input	sequence,	yet	 it	maintained	an	 identically	coded	amino	acid	sequence.	This	
new	nucleotide	 sequence	was	 thus	 resistant	 to	 the	RNAi-induced	 gene	 silencing	 used	
experimentally	to	achieve	protein	knockdown	(Figure	2-B).	
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Figure	2-B:	Scheme	for	creating	RNAi-Resistant	Proteins	
	
	
	
	
	
	
RNAi-Resistant	Core	Cleavage	Complex	factors:	RNAi-Resistant	protein	factors	were	
constructed	 by	 changing	 the	 third	 (wobble)	base	of	every	 codon	within	 the	 target	
region	 of	 exogenously	 introduced	 dsRNA.	 Codon	bias	 for	Drosophila	melanogaster	
was	 taken	 into	 account	 when	 designing	 the	 RNAi-Resistant	 nucleotide	 sequence	
(Schulz	et	al.,	2009).	
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	A	 DNA	 fragment	 corresponding	 to	 the	 ~500bp	 RNAi-target	 region	was	 then	
synthesized	as	a	GeneArt®	Strings™	DNA	Fragment	by	Life	Technologies	 (Grand	 Island,	
NY).	 Each	 RNAi-R	 GeneArt	 String	 and	 corresponding	 Symplekin,	 CPSF73	 or	
CPSF100::pENTRTMD-TOPO	were	digested	with	 restriction	enzymes	who’s	 sites	 flanked	
the	dsRNA	targeting	region	and	the	RNAi-R	fragment	was	substituted	for	the	wild	type	
piece	to	create	RNAi-R	Symplekin,	CPSF73	and	CPSF100::pENTRTMD-TOPO.	Ligation	of	the	
RNAi-resistant	DNA	piece	was	 performed	using	DNA	T4	 Ligase	 (Promega),	 and	proper	
ligationwas	confirmed	via	 restriction	digest	and	Sanger	sequencing.	RNAi-R	Symplekin,	
CPSF73	 and	CPSF100::pENTRTMD-TOPO	were	 each	 recombined	with	pAHW	and	pAWH	
destination	vectors	as	described	above	for	the	synthesis	of	each	pENTRTMD-TOPO	entry	
vector.	 Proper	 recombination	 was	 again	 confirmed	 via	 restriction	 digest	 and	 Sanger	
sequencing.		
	
Creation	of	stable	Drosophila	Dmel-2	tissue	culture	lines:	
	
Full	 length/mutant	 CCC	 factor::pAHW	 or	 full	 length/mutant	 CCC	 factor::pAWH	
were	 transfected	 into	 Drosophila	 Dmel-2	 cells	 with	 Effectene	 Transfection	 Reagent	
(Qiagen)	 according	 to	 the	 manufacturer’s	 protocol.	 The	 pCoBlast	 vector	 (Invitrogen)	
containing	 a	 Blasticidin	 resistance	 gene	 was	 co-transfected	 to	 enable	 selection	 of	
successfully	transfected	cells.	Cells	were	grown	in	SF-900	II	SFM	(Gibco)	and	maintained	
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at	 27°C	 under	 normal	 atmospheric	 conditions.	 48-hours	 post-transfection,	 Blasticidin	
(25ug/ml)	was	added	to	the	media	to	select	for	stably	transfected	cells.	Cells	were	split	
and	passaged	into	fresh	selective	media	every	5	days	to	a	concentration	of	1	x	106/mL.	
Stable	transfection	of	each	individual	CCC	factor	was	confirmed	via	Western	Blot	(WB)	
with	 anti-HA	 antibody	 (Covance,	 Princeton	NJ).	 Liquid	 nitrogen	 freezer	 stocks	 of	 each	
stable	 cell	 line	 were	 created	 by	 growing	 stably	 transfected	 cells	 to	 a	 density	 of	 10	 x	
106/mL,	pelleting	the	cells	in	Microcentrifuge	tubes,	decanting	selective	growth	medium,	
and	 re-suspending	 the	 cell	 pellet	 in	 SF-900	 SFM	 +	 10%	 DMSO.	 Cell	 suspension	 was	
transferred	to	a	2mL	cryo-vial,	placed	into	an	ethanol	immersed	rack	with	sealed	lid,	and	
kept	 in	 the	 -80	deg	C	 freezer	 for	a	minimum	of	24	hours.	This	procedure	ensures	 cell	
suspension	cools	at	a	 rate	of	1	deg	C	/	min.	24-48	hours	after	being	 in	 the	 -80	deg	C.	
freezer,	cryo-vials	were	placed	into	a	Liquid	Nitrogen	storage	tank	for	long-term	storage.	
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Figure	2-C:	Schematic	illustration	of	vector	transfection	and	Stable	Cell	Line	Creation	
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Schematic	illustration	of	the	co-transfection	of	both	the	desired	destination	vector	
(pAHW/pAWH)	 and	 the	 pCoBlast	 vector	 into	 Dmel-2	 cells.	 The	 pCoBlast	 vector	
contains	a	Blasticidin	resistance	gene,	so	48-hrs	post	transfection	Blasticidin	is	added	
to	 the	 cell	 culture	 media	 to	 promote	 integration	 of	 the	 vectors	 into	 the	 Dmel-2	
genome.		
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RNAi,	whole-cell	lysate	preparation,	nuclear	extract	preparation	and	RNA	isolation:	
	
RNAi	was	performed	as	described	(Sullivan	et	al.	2009).	Essentially	on	Day	1	of	the	
knockdown	experiment	2	x	106		Dmel-2	cells	in	2mL	of	SF-900	SFM	were	plated	in	each	
well	of	a	6-well	tissue	culture	plate.	dsRNA	(1ug	dsRNA/	1	x	106	cells)	targeting	either	the	
ORF	of	a	specific	core	cleavage	complex	protein	or	control	dsRNA	targeting	the	ORF	of	the	
LacZ	gene	was	ejected	directly	onto	the	cell	culture	within	each	well.	The	same	procedure	
of	ejecting	dsRNA	onto	the	cell	culture	was	repeated	exactly	24-hours	later	(Day	2)	and	
48-hours	later	(Day3).	On	day	3,	however,	the	total	cell	culture	volume	was	split	into	2	
wells,	original	cell	culture	volume	restored	via	the	addition	of	SF-900	SFM,	and	the	same	
concentration	of	dsRNA	was	added	to	both	split	wells.		On	day	5,	the	cells	were	counted	
with	a	Nexcelom	cell	counter	and	harvested	for	analysis.	To	make	whole	cell	lysates	for	
use	in	downstream	applications	(IP	and	WB	experiments),	the	appropriate	number	of	cells	
(typicaly	5	x	106	RNAi-depleted	or	control	cells	per	IP/WB)	were	pelleted,	washed	twice	
with	1mL	1x	PBS,	and	were	lysed	with	appropriate	volume	RIPA	buffer	(50mM	Tris-HCL	
(pH	8),	150m	NaCL,	1%	Nonidet	P-40,	0.25%	Na	deoxycholate)	plus	5uL	100x	Halt	Protease	
inhibitor	(Thermo	Scientific).	Cells	were	rotated	at	4°C	for	10	minutes	to	ensure	complete	
lysis	and	then	centrifuged	at	4°C	for	15	min	at	14,000	rpm	to	remove	all	cellular	debris.	
The	supernatant	was	transferred	to	a	new	tube	and	filtered	through	a	1mL	syringe	with	a	
26	Gauge	needle	to	shear	the	chromatin.	NEs	were	prepared		as	described	(Sullivan	et	al.	
2009)	from	1	x	108	cells	and	then	flash	frozen	in	liquid	N2	and	stored	at	-800C.	Whole	cell	
lysates	and	NEs	were	used	for	immunoprecipitations	(IPs)	and	protein	expression	analysis.		
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Total	RNA	was	extracted	from	RNAi-depleted	or	control	cells	with	TRIzol	Reagent	
(Sigma)	as	described	previously	for	use	in	S1	assays	(Sullivan	et	al.	2009).		
	
Antibodies:	
	
	 Monoclonal	 and	 polyclonal	 HA	 antibodies	 (Cat	 #s	 MMS-101R	 and	 PRB-101C,	
respectively,	Covance,	Princeton	NJ)	were	used	for	both	IP	(3uL	Ab/IP)	and	WB	(1:1000).	
Anti-CPSF73,	 anti-Symplekin	 and	 anti-CPSF100	 antibodies	 were	 described	 previously	
(Sullivan	 et	 al.	 2009).	 For	WB,	 antibodies	were	 used	 at	 1:1000.	 Secondary	 antibodies	
conjugated	 to	 HRP	were	 used	 at	 1:5000.	 Pico	 or	 Fempto	 ECL	 (Bio	 Rad)	 was	 used	 for	
visualizing	blots	via	the	use	of	X-ray	radiography	film.	
	
Immunoprecipitation	and	S1	nuclease	protection	assay:	
	
Immunoprecipitation	experiments-	 IP	of	HA-tagged	proteins	were	performed	as	
described	(Sullivan	et	al.	2009).	Essentially	Dmel-2	whole	cell	lysate	was	rotated	at	4°C	for	
1hr-overnight	with	Protein	A/G	PLUS-Agarose	beads	(Santa	Cruz	Biotechnology)	coated	
with	either	commercial	HA-antibody	for	IP	of	exogenously	expressed	tagged	protein	or	
appropriate	 polyclonal	 serum	 based	 antibody	 for	 IP	 of	 endogenous	 protein.	 Protein	
bound	beads	were	washed	4	x	1mL	RIPA	buffer,	SDS-load	dye	added,	and	boiled	at	100°C	
for	5	min	to	denature/release	IP’ed	and	Co-IP’ed	proteins	from	Protein	A/G	PLUS-Agarose	
beads.	Samples	were	run	on	10%	SDS-PAGE	gels,	 transferred	to	PVDF	membrane,	and	
probed	for	core	cleavage	complex	proteins	with	corresponding	antibodies.		
	S1	nuclease	protection	assay-	S1	nuclease	protection	assay	was	also	performed	as	
described	(Sullivan	et	al.	2009).	The	S1	nuclease	protection	assay	used	in	this	study	was	
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designed	to	assess	histone	pre-mRNA	3’-end	processing.	Specifically,	a	~675	nucleotide	
radiolabeled	probe	designed	to	be	complementary	to	the	3’-UTR	(~300	nucleotides)	of	
the	Drosophila	histone	2A	(H2A)	pre-mRNA	followed	by	the	proceeding	~350	nucleotides	
downstream	of	the	proper	3’-end	cleavage	site	was	cloned	into	a	specific	DNA	vector.	The	
dsDNA	 vector	 was	 double	 digested	 with	 restriction	 enzymes	 so	 that	 the	 initial	 20	
nucleotides	at	the	5’-end	of	the	probe	(far	3’	intergenic	region	of	H2A	gene)	were	random	
non-complementary	nucleotide	sequence	enabling	read-through	transcription	of	the	H2A	
gene	 past	 the	 proper	 cleavage	 site	 and	 all	 cryptic	 downstream	 poly(A)	 sites	 could	 be	
distinguished	from	the	probe	itself.	The	other	dsDNA	end	generated	via	the	double	digest	
left	a	5’-overhang	so	the	probes	3’-end	would	be	filled	in	with	Klenow	(NEB)	in	a	reaction	
containing	[α-32P]	dCTP	as	the	radionuclide,	thus	synthesizing	a	radiolabeled	H2A	pre-
mRNA	probe.	15ug	total	cellular	RNA	was	 incubated	with	 the	radiolabeled	H2A	mRNA	
probe	overnight	at	52°C.	Hybridized	RNA	was	then	treated	with	S1	nuclease,	degrading	
single	 stranded	 RNA	 (ssRNA),	 and	 RNA	 was	 resuspended	 in	 20	 μL	 RNA	 loading	 dye	
(containing	both	bromophenol	blue	and	xylene	cyanol)	and	run	on	a	pre-electrophoresed	
urea/acrylamide	gel.	Gel	was	dried	and	expose	to	phosphor	screen	or	film	overnight	and	
read	by	a	Stormscanner	(phosphor	screen)	or	developed	using	film.		
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Figure	2-D:	Schematic	of	S1	Nuclease	Protection	Assay	use	to	detect	Histone	mRNA	
misprocessing	
	
	
	
	 	
n
n
n
FIGURE	2-D.	CCCs	with	Symplekin	C-terminal	residues	can	use	downstream	poly(A)	
sites	for	H2A	mRNA	3ʹ	end	processing.	Above	is	a	schematic	of	the	histone	2A	(H2A)	
mRNA	3ʹ	end.	Cis	elements	required	for	proper	processing	are	the	stem–loop	(SL)	and	
the	 histone	 downstream	 element	 (HDE).	 The	 appropriate	 cleavage	 site	 and	 the	
properly	 processed	H2A	 3ʹ-end	 are	marked	with	 filled	 arrows.	Downstream	 cryptic	
polyadenylation	signals	and	misprocessed	products	resulting	from	use	of	these	signals	
are	 labeled	 with	 open	 arrows.	 If	 neither	 the	 proper	 cleavage	 site	 nor	 cryptic	
polyadenylation	signals	can	be	used	for	processing,	an	extended	3ʹ	UTR	product	results	
(RT).	 The	 3ʹ-end	 labeled	DNA	S1	 nuclease	assay	probe	will	hybridize	 to	all	of	 these	
products.	 The	 5ʹ	 20	 nt	 of	 the	 probe	 (zig-zag	 line)	 are	 vector	 sequence	 and	 cannot	
anneal	to	the	H2A	3ʹ-end	products.	Adapted	from	Michalski	and	Steiniger,	(2015).	
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IP	Quantification	and	S1	assay	quantification:	
	
IP	 quantitation	 -	 Blots	 were	 scanned	 at	 600	 PPI	 and	 analyzed	 using	 ImageJ	
software.	 Intensity	 of	 protein	 bands	 representing	 IP	 or	 co-IP	 were	 determined	 and	
compared	 to	 the	 intensity	 of	 the	 corresponding	 input	 band	 (representing	 5%	 of	 the	
sample).	 The	 ratio	 of	 IP	 or	 co-IP	 intensity	 to	 input	 intensity	 was	 multiplied	 by	 5	 to	
determine	the	percentage	of	total	protein	immunoprecipitated	from	the	sample.	
S1	Assay	quantitation	-	Two	independent	experiments	were	quantitated	for	each	
S1	 experiment.	 Dried	 6%	 Urea/TBE	 sample	 gels	 were	 placed	 on	 phosphoscreens	
overnight.	Phosphoscreens	were	scanned	using	a	STORM	Scanner	and	images	were	saved	
as	 TIFF	 files.	 The	 TIFF	 files	 were	 imported	 into	 ImageJ	 software	 and	 subsequently	
analyzed.	Peak	areas	were	determined	for	bands	corresponding	to	RT,	misprocessed	and	
properly	 processed	 H2A	 mRNAs.	 The	 sum	 total	 of	 all	 peaks	 in	 each	 lane	 was	 then	
determined	and	the	area	for	each	peak	(band)	was	divided	by	the	sum	total	of	peaks	in	
that	 lane	 to	 give	 a	 percentage.	 The	 percentages	 were	 averaged	 and	 the	 standard	
deviation	calculated	for	all	products	in	each	sample.		
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CHAPTER	3: 
In	vivo	characterization	of	the	Drosophila	mRNA	3ʹ	end	processing	
core	cleavage	complex	
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Introduction	
An	 initial	 draft	 of	 the	 introduction	 presented	 in	 this	 section	 was	 completed	 by	 me.	
Revisions	were	completed	by	myself	and	Dr.	Steiniger.	
	
Metazoan	 pre-mRNAs	 require	 extensive	 processing	 be-	 fore	 becoming	mature	
mRNAs.	One	important	maturation	step	is	3ʹ	end	processing.	Canonical	polyadenylated	
[poly(A)]	 pre-mRNAs	 are	 cleaved	 between	 a	 highly	 conserved	 AAUAAA	 and	 a	 less	
conserved	 G-	 or	 G/U-rich	 downstream	 element	 followed	 by	 polyadenylation	 of	 the	
upstream	mRNA.	Maturation	of	histone	pre-mRNAs	only	requires	a	single	cleavage	event	
between	 an	 upstream	 stem–loop	 (SL)	 analogous	 to	 the	 AAUAAA	 in	 canonical	 poly(A)	
mRNAs,	 and	 the	 histone	 downstream	 element	 (HDE)	 (Dominski	 et	 al.	 1999).	 Histone	
mRNAs	 are	 not	 polyadenylated,	 ending	 in	 the	 SL.	 These	 different	 cis	 elements	 recruit	
either	histone	or	canonical	poly(A)	mRNA	specific	processing	factors.	The	SL	is	bound	by	
the	 stem–loop	 binding	 protein	 (SLBP)	 while	 the	 HDE	 interacts	 with	 the	 U7	 RNA	
component	 of	 the	 U7	 snRNP	 (Marzluff	 et	 al.	 2008).	 The	 U7snRNP	 recruits	 processing	
factors	 via	 an	 interaction	between	 Lsm11	and	 FLASH	 (Burch	et	 al.	 2011;	 Sabath	et	 al.	
2013).	 The	highly	 conserved	AAUAAA	 characteristic	 of	 canonical	 poly(A)	mRNAs	binds	
CPSF30	and	WDR33	(Chan	et	al.	2014;	Schönemann	et	al.	2014)	and	CstF64	contacts	the	
less	con-	served	G-	or	G/U-rich	element	(Takagaki	and	Manley	1997).	While	both	types	of	
mRNAs	utilize	unique	proteins,	cleavage	and	polyadenylation	specificity	factor	(CPSF)73,	
CPSF100,	 and	 Symplekin	 are	 essential	 for	 proper	 processing	 of	 all	 metazoan	 mRNAs	
(Sullivan	et	al.	2009).	CPSF73	is	the	endonuclease	responsible	for	catalyzing	the	cleavage	
reaction	(Ryan	et	al.	2004;	Dominski	et	al.	2005a;	Mandel	et	al.	2006).	CPSF100	forms	a	
heterodimer	with	CPSF73	and	Symplekin	acts	as	a	scaffolding	protein	onto	which	other	
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cleavage	and	polyadenylation	proteins	bind	(Takagaki	and	Manley	2000;	Dominski	et	al.	
2005b).		
Because	the	CCC	plays	an	integral	role	in	3ʹ	end	processing	of	all	metazoan	pre-
mRNAs,	 determining	 biologically	 relevant	 binding	 interactions	 in	 this	 complex	 is	
important.	 Details	 describing	 CPSF73,	 CPSF100,	 and	 Symplekin	 interactions	 are	 not	
available	as	no	structural	data	corresponding	to	the	CCC	have	been	published	and	X-ray	
crystal	structures	of	individual	components	are	limited.	The	three-	dimensional	structure	
of	 human	 CPSF73	 reveals	 that	 the	 N-	 terminal	 460	 amino	 acids	 contain	 β-metallo	
lactamase	and	β-CASP	domains	(Fig.	1A;	Mandel	et	al.	2006).	The	interface	of	these	two	
domains	form	the	nuclease	active	site	(Mandel	et	al.	2006).	The	crystal	structure	of	yeast	
CPSF100	 closely	 resembles	 the	 domain	 architecture	 of	 CPSF73	 (Mandel	 et	 al.	 2006).	
CPSF100	has	both	a	metallo-β-lactamase-like	domain	and	a	β-CASP	domain,	but	CPSF100	
active	site	residues	are	mutated	such	that	CPSF100	does	not	function	as	a	nuclease	(Fig.	
1A;	 Mandel	 et	 al.	 2006).	 Previous	 experiments	 led	 to	 hypotheses	 that	 C-terminal	
CPSF73/CPSF100	residues	may	be	important	for	heterodimerization	(Jenny	et	al.	1996).	
Structures	of	the	N-terminal	271	amino	acids	of	Symplekin	reveal	seven	pairs	of	α-helices	
comprising	 a	 HEAT	 domain	 (Fig.	 1A;	 Kennedy	 et	 al.	 2009;	 Xiang	 et	 al.	 2010).	 This	 N-
terminal	HEAT	domain	in	human	Symplekin	mediates	protein–	protein	interactions	and	
interacts	directly	with	Ssu72,	a	RNA	polymerase	II	carboxy-terminal	domain	(RNAPII	CTD)	
Ser5	phosphatase	that	is	required	for	mRNA	3ʹ	end	processing	in	yeast	(He	et	al.	2003;	
Krishnamurthy	 et	 al.	 2004;	 Xiang	 et	 al.	 2010).	 The	 C-terminal	 85	 amino	 acids	 of	 the	
Symplekin	 yeast	 homolog,	 Pta1,	 interact	with	 Ysh1	 (the	 yeast	 CPSF73	homo-	 log)	 in	 a	
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directed	yeast-two	hybrid	assay	and	full-length	Pta1	interacts	with	yeast	CPSF100	in	an	in	
vitro	pull-down	as-	say	(Ghazy	et	al.	2009).	Additionally,	full-length	Pta1	interacts	directly	
with	 the	 C-terminus	 of	 Ysh1	 (Zhelkovsky	 et	 al.	 2006).	 While	 the	 structure	 function	
relationship	has	been	investigated	for	regions	of	individual	CCC	components,	molecular	
de-	tails	for	the	complex	are	sparse.		
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Figure	3-1	
	
FIGURE	1.	
Stably	expressed,	HA-tagged	full-length	CCC	components	interact	with	endogenous	binding	partners	to	form	mixed	
CCCs.	(A)	Schematic	representations	of	Symplekin,	CPSF100,	and	CPSF73	are	shown.	HEAT,	metallo-β-lactomase	(MβL),	
and	β-CASP	shaded	boxes	indicate	the	location	of	distinct	structural	domains.	Numbers	listed	within	and	above	boxes	
indicate	 amino	 acid	 positions.	 Those	 numbers	 with	 three	 letter	 amino	 acid	 abbreviations	 correspond	 to	 catalytic	
residues.	(B)	Schematic	of	one	repeat	(∼5	kb)	within	the	Drosophila	histone	gene	locus.	The	direction	of	transcription	is	
shown	directly	below	each	histone	gene	(H1,	H2A,	H2B,	H3,	and	H4).	The	number	of	nucleotides	between	each	histone	
gene	is	shown	above.	(C–E)	Full-length	HA-tagged	Symplekin	(C),	CPSF100	(D),	and	CPSF73	(E)	were	immunoprecipitated	
(IP)	from	whole-cell	lysates	with	an	anti-HA	antibody.	IPs	were	separated	with	SDS-PAGE,	transferred	to	a	membrane,	
and	probed	with	anti-HA,	anti-Symplekin,	anti-CPSF73,	and	anti-CPSF100	antibodies.	Lane	1	is	5%	input,	lanes	2,3	are	
controls	where	IPs	were	performed	in	the	absence	of	antibody	(beads)	or	with	a	nonspecific	antibody	(anti-Myc),	and	
lane	4	shows	the	experimental	IP.	The	top	panel	of	each	WB	set	is	the	IP	of	HA-tagged	protein	while	the	lower	panels	
represent	the	co-IPs	of	CCC-binding	partners.	
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We	define	CPSF73,	CPSF100,	and	Symplekin	as	the	core	cleavage	complex	(CCC).	
These	 three	 proteins	 form	 a	 tight	 complex	 in	 vivo	 as	 evidenced	 by	 co-
immunoprecipitation	(co-IP)	in	stringent	buffer	conditions	and	codepletion	of	the	other	
two	 CCC	 factors	 when	 one	 CCC	 component	 is	 RNAi-depleted	 (Sullivan	 et	 al.	 2009).	
Previous	 investigations	 in	 Drosophila	 tissue	 culture	 (Dmel-2)	 cells	 of	 CCC	 function	 on	
endogenous	histone	mRNAs	reveal	that	this	complex	is	required	for	proper	histone	2A	
(H2A)	 3ʹ	 end	 processing.	 If	 a	 CCC	 component	 is	 RNAi-depleted,	 cleavage	 at	 the	 site	
between	the	SL	and	the	HDE	is	less	efficient	resulting	in	a	read	through	(RT)	H2A	mRNA	
with	an	extended	3ʹ	untranslated	region	(UTR).	(Wagner	et	al.	2007;	Sullivan	et	al.	2009).	
The	RT	product	is	the	dominant	misprocessed	H2A	product	in	these	cells.	RNAi-depletion	
of	histone-specific	factors	U7	snRNA,	SLBP,	and	FLASH	also	result	in	less-efficient	use	of	
the	proper	H2A	processing	site.	But,	in	contrast	to	RNAi-	depletion	of	CCC	components,	
these	cells	can	use	cryptic	poly(A)	signals	downstream	from	the	proper	cleavage	site	to	
process	these	mRNAs	resulting	in	poly(A)	histone	mRNAs	(Lanzotti	et	al.	2002;	Sullivan	et	
al.	2009;	Tatomer	et	al.	2014).	 	mRNA	 3ʹ	 end	 processing	 by	 the	 CCC	 occurs	
cotranscriptionally	 and	 coupling	 of	 RNA	 synthesis	 and	 processing	 is	 co-	 ordinated	 by	
modifications	 in	 the	 repetitive	 heptad	 of	 the	 RNAPII	 CTD	 (Greenleaf	 1993;	 Hsin	 and	
Manley	 2012).	Direct	 interactions	between	 the	RNAPII	 CTD,	 CPSF	 and	CstF	 have	been	
observed	 and	 removal	 of	 the	 RNAPII	 CTD	 causes	 inefficient	 mRNA	 3ʹ	 end	 processing	
(McCracken	et	al.	1997).	3ʹ	end	processing	factor	CPSF73	occupies	both	5ʹ	and	3ʹ	ends	of	
candidate	 mammalian	 genes	 while	 polyadenylation	 factors	 CstF50	 and	 CstF77	
predominately	occupy	the	3ʹ	ends	(Glover-Cutter	et	al.	2008;	Ni	et	al.	2008;	Sullivan	et	al.	
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2009).	Additional	data	show	that	the	CPSF	complex	is	recruited	to	the	5ʹ	end	by	TFIID	and	
remains	 associated	 with	 RNAPII	 throughout	 transcription	 elongation	 (Dantonel	 et	 al.	
1997).	Recruitment	of	mRNA	3ʹ	end	processing	factors	to	the	RNAPII	CTD	correlates	with	
specific	 phosphorylation	 of	 CTD	 heptad	 repeat	 positions	 Ser5	 and	 Ser2.	 In	Drosophila	
tissue	 culture	 cells,	 impairment	 of	 Ser2	 phosphorylation	 results	 in	 less-efficient	
recruitment	of	mRNA	3ʹ	end	processing	factors	to	the	3ʹ	ends	of	genes	(Ni	et	al.	2008).	
Finally,	the	N-	terminal	271	amino	acids	of	human	Symplekin	interact	with	Ssu72,	a	RNAPII	
CTD	Ser5	phosphatase	that	is	required	for	mRNA	3ʹ	end	processing	in	yeast	(He	et	al.	2003;	
Krishnamurthy	et	al.	2004;	Xiang	et	al.	2010).	Taken	together,	these	data	support	a	model	
in	which	mRNA	3ʹ	end	processing	is	cotranscriptional.		
Previous	 work	 indicates	 that	 histone	 pre-mRNA	 3ʹ	 end	 processing	 is	 also	
cotranscriptional.	In	Drosophila,	the	his-	tone	gene	locus	consists	of	100	tandem	repeats	
of	 a	 5-kb	 region	 containing	 a	 single	 copy	 of	 each	 replication-dependent	 histone	 gene	
separated	by	<500	nt	 (Fig.	1B).	Each	alternating	gene	 is	 transcribed	 from	the	opposite	
strand,	requiring	coordinated	transcription	termination	and	3ʹ	end	processing	to	prevent	
transcription	into	neighboring	genes	(Sullivan	et	al.	2009).	Evidence	supporting	this	model	
is	observed	in	histone	mRNA	3ʹ	end	sequences	obtained	from	the	modENCODE	project	
(Celniker	et	al.	2009).	Sequencing	reads	are	not	observed	downstream	from	the	histone	
3ʹ	SL	and	cleavage	site.	Additionally,	RNAPII	pause	sites	downstream	from	the	histone	
mRNA	3ʹ	 end	 cleavage	 site	 have	 been	 identified	 that	 affect	 histone	mRNA	processing	
(Adamson	and	Price	2003)	and	CCC	components	Symplekin	and	CPSF73	ChIP	to	histone	3ʹ	
ends	(Sullivan	et	al.	2009).	Finally,	phosphorylation	of	RNAPII	CTD	heptad	residue	Thr4	is	
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specifically	 required	 for	 histone	mRNA	 3ʹ	 end	 processing.	 SLBP	 and	 CPSF100	 are	 not	
recruited	to	histone	genes	if	Thr4	is	not	phosphorylated	(Hsin	et	al.	2011).	Collectively,	
these	 data	 support	 a	model	 in	 which	 pre-mRNA	 3ʹ	 end	 processing,	 transcription	 and	
termination	are	tightly	coordinated.		
Recent	X-ray	crystallographic	 investigations	of	CPSF73,	CPSF100,	and	Symplekin	
have	 focused	 on	 individual	 components	 and	 have	 resulted	 in	 only	 partial	 structures	
(Mandel	 et	 al.	 2006;	 Kennedy	 et	 al.	 2009;	 Xiang	 et	 al.	 2010).	 Additionally,	 previous	
analyses	of	CCC	component	binding	 interactions	are	 incomplete	concentrating	on	only	
two	of	the	three	factors	or	were	performed	in	vitro	or	using	bioinformatics	(Jenny	et	al.	
1996;	Kyburz	et	al.	2003;	Dominski	et	al.	2005b;	Zhelkovsky	et	al.	2006).	To	further	define	
CPSF73,	CPSF100,	and	Symplekin	binding	interactions,	we	developed	a	novel	Drosophila	
cell	 culture	 system	 in	which	 tagged,	mutant	 components	were	 individually	 expressed.	
Interaction	 of	 these	 exogenous	 factors	 with	 endogenous-binding	 partners	 identified	
important	binding	regions	of	CPSF73,	CPSF100,	and	Symplekin	in	vivo.	Furthermore,	the	
activity	of	mutant	component	containing	CCCs	was	assessed	on	an	endogenous	histone	
mRNA	 to	 demonstrate	 domains	 important	 for	 cotranscriptional	 histone	mRNA	 3ʹ	 end	
processing.		
Results	
	
All	 the	 experiments	 presented	 in	 this	 section	 (including	 the	 experimental	 designs	 and	
experimental	approaches)	were	completed	by	me.	An	initial	draft	of	the	“Results”	section	
was	 completed	 by	 me.	 Revisions	 to	 the	 writing	 were	 completed	 by	 myself	 and	 Dr.	
Steiniger.	
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Development	 and	 validation	 of	 a	 Dmel-2	 expression	 system	 to	 study	 in	 vivo	 protein	
interactions	in	the	CCC		
	
Our	goal	was	 to	understand	CCC	 interactions	 in	 vivo.	Therefore,	we	needed	 to	
develop	 a	 system	 to	 express	 tagged	 CCC	 components	 that	 could	 both	 integrate	 into	
complexes	 with	 endogenous-binding	 partners	 (form	 mixed	 CCCs)	 and	 be	
immunoprecipitated	 (IPed).	 To	 accomplish	 this	 goal,	 full-length,	 wild-type	 CPSF73,	
CPSF100,	 and	Symplekin	 sequences	were	 first	 cloned	downstream	 from	a	 constitutive	
promoter	in	plasmids	conferring	either	an	N-	or	C-terminal	HA	tag.	These	plasmids	were	
then	transfected	into	Dmel-2	cells	and	maintained	under	selection	to	create	polyclonal	
Dmel-2	cells	stably	expressing	CCC	factors.	Stable	expression	of	CCC	factors	did	not	affect	
the	viability	of	Dmel-2	cells.	Extracts	used	for	IP	were	prepared	from	these	cells	and	anti-
HA	Western	blot	(WB)	confirmed	expression	of	full-	length	HA-tagged	CCC	proteins	(Fig.	
1C–E,	lane	1	or	Fig.	2B).	To	validate	that	stably	expressed	CCC	factors	could	be	IPed	and	
form	mixed	CCCs,	each	CCC	component	was	individually	IPed	from	Dmel-2	stable	cell	line	
whole-cell	 lysates	 followed	by	WB	for	co-IP	of	endogenous-binding	partners.	 IP	of	HA-
tagged	Symplekin	successfully	co-IPed	endogenous	CPSF73	and	CPSF100	(Fig.	1C).	IP	of	
HA-tagged	CPSF100	co-IPed	endogenous	Symplekin	and	CPSF73	(Fig.	1D).	IP	of	HA-tagged	
CPSF73	co-IPed	endogenous	Symplekin	and	CPSF100	 (Fig.	1E).	 In	each	case,	 significant	
amounts	of	endogenous-binding	partners	were	observed	(Fig.	3B,D,F).	No	IP	of	exogenous	
factors	or	co-IP	of	endogenous	proteins	was	observed	 in	no	(Beads)	or	nonspecific	 (α-
Myc)	antibody	controls	(Fig.	1C–E,	 lanes	2,3).	These	data	 indicate	that	HA-	tagged	CCC	
components	can	be	stably	expressed	in	Dmel-2	cells	without	affecting	cell	viability.	Also,	
the	HA	fusion	does	not	prevent	CCC	factor	expression	or	CCC	formation	with	endogenous-
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binding	partners.	RNAi-	depletion	of	endogenous	CCC	factors	 is	not	 required	to	assess	
interactions	within	the	CCC.		
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Figure	3-2	
	
FIGURE	2.	HA-tagged	deletion	mutants	of	Symplekin,	CPSF100,	and	CPSF73	can	be	stably	ex-	pressed	in	Dmel-2	cells.	
(A)	Schematics	of	Symplekin	(top),	CPSF100	(middle),	and	CPSF73	(bot-	tom)	deletion	mutants	used	for	in	vivo	binding	
assays	 are	 shown	below	each	 full-length	 protein.	 Each	mutant	 is	 defined	by	 the	 amino	 acids	 contained	within	 the	
deletion,	for	example	(1–271).	The	C-terminal	amino	acid	of	each	mutant	is	written	above	the	full-length	CCC	factor.	
The	nucleotides	targeted	by	dsRNA	are	defined	by	a	solid	rectangle.	(B)	HA-tagged	full	length	(lanes	2,7,12)	and	N-	and	
C-terminally	truncated	CPSF73	(lanes	3–5),	CPSF100	(lanes	8–10),	and	Symplekin	(lanes	13–18)	deletion	mutants	were	
stably	expressed	in	Dmel-2	cells.	Whole-cell	lysates	from	these	strains	were	separated	with	SDS-PAGE,	transferred	to	a	
membrane,	and	probed	with	an	anti-HA	antibody	to	confirm	expression.	Amino	acids	comprising	the	deletion	mutant	
are	shown	following	the	protein	name	above	the	WB.	Molecular	weight	(MW)	markers	for	lanes	1–14	are	on	the	left.	
MW	markers	for	lanes	15–18	are	on	the	right.	 
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Symplekin	amino	acids	927–1080,	CPSF100	amino	acids	648–756,	and	CPSF73	amino	acids	
552–684	are	required	for	CCC	formation		
	
IP	of	mixed	CCCs	from	Dmel-2	whole-	cell	lysates	confirms	that	CCCs	having	both	
exogenous	and	endogenous	components	can	be	formed	and	isolated.	Our	next	goal	was	
to	 determine	which	 regions	 of	 CPSF73,	 CPSF100,	 and	 Symplekin	 are	 required	 for	 CCC	
formation.	 To	 address	 this,	we	 constructed	N-	 and	 C-	 terminal	 CPSF73,	 CPSF100,	 and	
Symplekin	mutants.	Deletion	positions	were	determined	using	Phyre2	prediction	 soft-	
ware	 (Kelley	and	Sternberg	2009)	and	were	only	made	 in	disordered	regions	 (Fig.	2A).	
Symplekin	mutants	were	amino	acids	1–271	(N-terminal),	272–1165	(C-terminal),	272–
1080,	272–926,	272–	756,	and	272–625.	CPSF100	mutants	were	amino	acids	1–524	(N-
terminal),	525–756	(C-terminal),	and	525–647.	CPSF73	mutants	were	amino	acids	1–	465	
(N-terminal),	 466–684	 (C-terminal),	 and	 466–552.	 These	 mutants	 were	 constructed,	
transfected,	 and	 stably	 expressed	 as	 their	 full-length	 counterparts	 in	 Dmel-2	 cells.	
Expression	was	confirmed	in	whole-cell	lysates	with	an	anti-HA	WB	(Fig.	2B).	All	mutants	
IP	with	an	α-HA	antibody	were	detected	by	WB	with	an	α-HA	antibody	(Fig.	3A,C,E,	top	
WB).		
The	large	C-terminal	HA-tagged	Symplekin	mutant	(Symp(272–1165))	binds	both	
CPSF73	and	CPSF100,	while	the	N-terminal	mutant	(Symp(1–271))	binds	neither	protein	
(Fig.	3A,	lanes	6,8,	3B).	Symp(272–1165)	IPs	more	CPSF73	than	full-length	Symplekin	(Fig.	
3B).	 Increasing	 deletion	 of	 C-terminal	 resi-	 dues	 from	 Symp(272–1165)	 results	 in	
progressively	 less-efficient	 CCC	 formation	 (Fig.	 3B).	 Symp(272–1080)	 co-IPs	 CPSF73	
comparable	with	full-length	Symplekin	(Fig.	3B).	Symp(272–926)	and	Symp(272–758)	also	
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bind	 CPSF73	 and	 CPSF100,	 but	 to	 a	 lesser	 extent	 than	 full-length	 Symplekin(Fig.3B).	
Symp(272–	625)	does	not	co-IP	CPSF73	or	CPSF100	(Fig.	3B).	Two	additional	Symplekin	
mutants,	 Symp(272–525)	 and	Symp(272–	395),	having	even	 fewer	C-terminal	 residues	
also	did	not	co-IP	endogenous	CPSF73	or	CPSF100	(data	not	shown).	These	data	indicate	
that	the	first	271	amino	acids	of	Symplekin	are	not	required	for	CCC	formation.	Symplekin	
aminoacids272–1080	are	sufficient	 for	CCC	formation	while	amino	acids	927–1080	are	
essential	for	interaction	with	CPSF73/CPSF100.		
IP	 of	 HA-tagged	 C-terminal	 CPSF100	 (100(525–756))	 also	 resulted	 in	 co-IP	 of	
endogenous	CCC-binding	partners	(Fig.	3C,D);	100(525–756)	binds	CPSF73	and	Symplekin	
comparable	with	full-length	CPSF100	(Fig.	3D),	while	N-terminal	100(1–524)	does	not	co-
IP	CCC-binding	partners	(Fig.	3D).	Deletion	of	an	additional	109	amino	acids	from	the	C-
terminus	of	the	CPSF100	C-terminal	mutant	(100	(525–647))	abolishes	co-IP	of	CPSF73	
and	Symplekin	(Fig.	3D).	These	data	indicate	that	amino	acids	525–756	of	CPSF100	are	
sufficient	for	CCC	formation	and	amino	acids	1–524	are	dispensable	for	interaction	with	
CPSF73	and	Symplekin.	CPSF100	amino	acids	648–756	are	required	for	CCC	formation.		
IP	of	HA-tagged	C-terminal	CPSF73	(73(466–684))	co-	IPed	Symplekin	and	CPSF100	
comparable	 with	 full-length	 CPSF73	 (Fig.	 3E,F),	 while	 the	 N-terminal	 CPSF73	 mutant	
(73(1–465))	cannot	participate	in	CCC	formation	(Fig.	3F).	Deletion	of	an	additional	133	
amino	acids	 from	the	C-terminus	of	 the	C-terminal	CPSF73	mutant	 (73(466–552))	pre-	
vents	Symplekin	binding,	but	interaction	with	CPSF100	is	maintained	(Fig.	3F).	These	data	
indicate	that	CPSF73	amino	acids	466–684	are	sufficient	for	interaction	with	CPSF100	and	
Symplekin	while	amino	acids	1–465	cannot	facilitate	CCC	formation.	Amino	acids	553–
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684	are	essential	for	binding	Symplekin	while	CPSF100	may	interact	with	CPSF73	amino	
acids	466–552.		
To	 ensure	 that	 phenotypes	 observed	 for	 mutant	 CCCs	 are	 attributable	 to	 the	
mutant	 CCC	 component,	 we	 investigated	 inclusion	 of	 corresponding	 full-length	
endogenous	CCC	components	in	CCCs	having	HA-tagged	full-length	and	mutant	factors.	
CCCs	including	full-length	HA-tagged	proteins	do	not	also	contain	endogenous	CCC	factors	
(Fig.	3A,C,E,	bottom	WB,	lanes	1–4).	While	CCC	antibodies	react	with	both	endogenous	
and	exogenous	CCC	factors,	the	full-length	HA-tagged	protein	in	each	IP	is	slightly	larger	
than	 the	 corresponding	 band	 in	 the	 input	 indicating	 that	 the	 HA-tagged	 protein	
dominates	 in	 the	 IP	 (Fig.	 3A,C,E,	 bottom	WB,	 cf.	 lanes	 1,4).	 The	HA-tagged	 protein	 is	
expressed	at	 less	than	endogenous	 levels	and	therefore	 is	not	visible	 in	the	 input	(Fig.	
3A,C,E,	bottom	WB,	lane	1).	All	HA-tagged	deletion	mutants	differ	significantly	in	size	from	
their	 full-length	 counterparts	 allowing	 detection	 of	 full-length	 endogenous	 CCC	
components	 in	 CCC	 IPs.	 None	 of	 the	 mixed	 complexes	 contain	 the	 corresponding	
endogenous-binding	partners	(Fig.	3A,C,E,	bottom	WB).		
Together,	these	data	support	a	model	in	which	one	Symplekin,	one	CPSF73,	and	
one	CPSF100	interact	to	form	the	CCC.	Generally,	the	C-termini	of	each	protein	mediate	
CCC	formation.	Specifically,	amino	acids	272–1080	of	Symplekin,	amino	acids	466–684	of	
CPSF73,	and	amino	ac-	ids	525–756	of	CPSF100	are	sufficient	for	binding,	while	Symplekin	
amino	acids	927–1080,	CPSF100	amino	acids	648–756	and	CPSF73	amino	acids	552–684	
are	 required	 for	 CCC	 formation	 (Fig.	 3G).	 CPSF73	 amino	 acids	 466–552	 may	 contact	
CPSF100	while	CPSF73	C-terminal	residues	553–684	are	essential	for	binding	Symplekin.		
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Figure	3-3	
	
FIGURE	3.	 Symplekin	 amino	 acids	 272–1080,	 CPSF100	 amino	 acids	 525–756,	 and	CPSF73	 amino	 acids	 465–684	 are	
sufficient	for	CCC	formation.	(A,C,E)	HA-tagged	Symplekin	mutants	(A),	HA-tagged	CPSF100	mutants	(C),	and	HA-tagged	
CPSF73	mutants	(E)	were	IPed,	separated,	and	probed	with	HA-	and	CCC-specific	antibodies.	Numbers	under	the	protein	
name	correspond	to	the	amino	acid	residues	comprising	each	mutant.	IP	of	full-	length	proteins	and	controls	(lanes	1–
4)	are	 included	for	reference.	(B,D,F	)	Percentage	of	 IP	or	co-IPed	proteins	corresponding	to	WBs	 in	A,	C,	and	E	are	
plotted.	Black	bars	are	percent	HA	IP,	gray	bars	are	percent	CPSF73	IP,	bars	with	diagonal	lines	are	percent	CPSF100	IP,	
and	bars	with	black	diamonds	are	percent	Symplekin	IP.	In	(B),	the	numbers	above	the	bars	correspond	to	percent	IP	
for	that	sample.	(G)	A	CCC-binding	model	is	shown.	The	C-termini	of	Symplekin,	CPSF73,	and	CPSF100	are	sufficient	for	
CCC	formation.		
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HA	RNAi-resistant	CCC	factors	express	simultaneously	with	RNAi-depletion	of	endogenous	
proteins	and	behave	as	wild-type	CCC	components		
	
After	elucidating	binding	interactions	in	the	CCC,	we	wanted	to	investigate	in	vivo	
activity	of	mutant	CCCs.	While	previous	experiments	with	HA-tagged	CPSF73,	CPSF100,	or	
Symplekin	containing	CCCs	were	performed	in	the	presence	of	endogenous	complexes,	
functional	wild-type	CCCs	mask	in	vivo	activity	of	mutant	CCCs.	To	focus	on	only	mixed	
CCCs,	we	RNAi-depleted	endogenous	CCC	components	while	expressing	RNAi-resistant	
(RNAi-R)	CCC	factors.	While	this	powerful	technique	has	been	utilized	before	(Ruepp	et	
al.	2011;	Chen	et	al.	2013),	it	is	a	novel	way	to	study	CCC	function.	RNAi-R	mRNAs	were	
constructed	 by	 introducing	 silent	mutations	 at	 the	wobble	 base	 of	 each	 codon	 in	 the	
RNAi-targeted	region	(Fig.	4A;	Schulz	et	al.	2009).		
Stable	 lines	 expressing	 HA-tagged	 full-length	 R-Symplekin,	 R-CPSF73,	 and	 R-
CPSF100	 were	 RNAi-depleted	 of	 the	 corresponding	 endogenous	 proteins.	 Symplekin,	
CPSF73,	 and	 CPSF100	 are	 efficiently	 RNAi-depleted	 when	 compared	 with	 either	 no	
double-stranded	or	nonspecific	RNA	 (LacZ)	 controls	 (Fig.	4B–D,	 top	panels,	 lanes	1–3).	
WBs	 with	 an	 anti-HA	 antibody	 show	 that	 RNAi-R	 CCC	 components	 are	 successfully	
expressed	 in	the	presence	of	RNAi	targeting	the	corresponding	CCC	factors	(Fig.	4B–D,	
bottom	panels,	lane	6).	Concurrent	expression	of	HA-tagged	proteins	and	RNAi-depletion	
is	 best	 observed	 for	 CPSF73;	 endogenous	 CPSF73	 is	 clearly	 RNAi-depleted	 while	 the	
slightly	larger	HA-tagged,	R-CPSF73	is	expressed	(Fig.	4D,	lanes	4–6).	This	phenomenon	is	
also	observed	for	Symplekin,	although	HA-tagged	Symplekin	is	less	of	the	total	Symplekin	
pool	as	assessed	by	comparing	the	amount	of	HA-tagged	and	endogenous	Symplekin	in	
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lane	6	 (Fig.	4B,	 lanes	4–6).	HA-tagged	and	endogenous	CPSF100	are	not	 resolved,	but	
reduced	CPSF100	levels	indicate	RNAi-depletion	of	endogenous	protein	with	concurrent	
expression	of	HA-tagged	CPSF100	(Fig.	4C,	lanes	4–6).	These	experiments	were	repeated	
for	each	HA-tagged	CCC	factor	mutant	to	ensure	that	RNAi-R	proteins	were	successfully	
expressed	 simultaneously	 with	 RNAi-depletion	 of	 endogenous	 CCC	 components	
(Supplemental	Fig.	1).	Finally,	RNAi-R	CCC	factors	IP	endogenous-binding	partners	much	
like	their	wild-type	counter-	parts	as	compared	with	no	and	nonspecific	antibody	controls	
(Fig.	4E–G).		
The	C-terminal	232	amino	acids	of	CPSF100	are	sufficient	for	the	formation	of	functional	
CCCs		
	
To	investigate	in	vivo	activity	of	mutant	CCC	complexes,	we	visualized	histone	H2A	
3ʹ	ends	using	an	S1	nuclease	assay.	In	Drosophila,	the	3ʹ	ends	of	replication-dependent	
histone	mRNAs	are	properly	processed	with	a	single	cleavage	between	a	conserved	stem–
loop	(SL)	and	the	histone	downstream	element	(HDE)	(Fig.	5A,	filled	arrow).	Misprocessing	
of	H2A	occurs	when	downstream	cryptic	polyadenylation	signals	recruit	3ʹ	end	processing	
factors	 resulting	 in	polyadenylated	H2A	mRNAs	 (Fig.	 5A,	open	arrows).	When	CPSF73,	
CPSF100,	 or	 Symplekin	 are	 RNAi-depleted,	 neither	 the	 SL/HDE	 nor	 the	 cryptic	
polyadenylation	 signals	 can	 be	 utilized	 for	 histone	 mRNA	 processing,	 resulting	 in	 an	
extended	3ʹ	UTR	or	read	through	(RT)	product	(Fig.	5A).	These	processed	H2A	mRNAs	are	
clearly	 observed	 following	 hybridization	 with	 a	 radioactively	 labeled	 probe	 and	 S1	
nuclease	digestion	(Fig.	5A,	probe).	This	assay	has	been	used	previously	to	investigate	H2A	
3ʹ	 end	 processing	 (Lanzotti	 et	 al.	 2002;	 Sullivan	 et	 al.	 2009).	We	 performed	 each	 S1	
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nuclease	assay	in	duplicate	followed	by	quantitation	of	the	amount	of	properly	processed,	
3ʹ	end	misprocessed	and	RT	H2A	mRNAs.	Averages	of	percent	nonproperly	processed	H2A	
mRNAs	are	included.		
RNAi-depletion	 of	 CPSF100	 causes	 H2A	 misprocessing	 when	 compared	 with	
negative	controls	(Fig.	5B,	cf.	lanes	2,3	to	lane	4).	RT	mRNA	is	21.6%	of	total	H2A	mRNA	
in	this	sample	and	is	the	primary	misprocessed	product	(Fig.	5E).	Previous	experiments	
are	 consistent	 with	 this	 result	 (Sullivan	 et	 al.	 2009).	 When	 R-CPSF100	 is	 expressed	
simultaneously	with	RNAi-depletion	of	endogenous	CPSF100,	the	amount	of	RT	is	9.3%	
(Fig.	5B,E).	Expression	of	R-CPSF100	partially	rescues	the	RNAi-depletion	defect	showing	
that	mixed	CCC	are	functional.	Expression	of	CPSF100(525–756)	results	in	11.6%	RT	H2A	
misprocessing	product	 indicating	this	mutant	also	rescues	the	effect	of	CPSF100	RNAi-
depletion	 (Fig.	5B,E).	 Expression	of	CPSF100(525–647)	does	not	 rescue	CPSF100	RNAi-
depletion	as	indicated	by	RT	levels	(20.5%)	comparable	with	the	CPSF100	RNAi	sample	
(Fig.	 5B,E).	Double-stranded	RNA	 for	 RNAi	 targets	 the	N-terminal	 region	of	 full-length	
CPSF100	(Fig.	2A),	therefore,	RNA-R	forms	of	CPSF100	(525–756)	and	CPSF100(525–647)	
did	not	have	to	be	constructed.	Collectively,	these	data	indicate	that	CCCs	containing	the	
minimal	region	of	CPSF100	required	for	CCC	formation	are	functional	and	that	the	first	
524	amino	acids	of	CPSF100	are	dispensable	for	proper	H2A	processing.		
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Figure	3-4	
 
 
 
FIGURE	4.	RNAi-resistant	 (RNAi-R)	CCC	 factors	 are	expressed	during	 simultaneous	RNAi-depletion	of	 corresponding	
endogenous	 proteins	 and	 form	 complexes	 with	 endogenous-binding	 partners.	 (A)	 RNAi-R	 CCC	 components	 were	
constructed	by	changing	the	third	(wobble)	base	of	every	codon	within	the	region	targeted	by	exogenously	introduced	
dsRNA.	 (B–D)	 HA-tagged	 R-Symplekin	 (B),	 R-CPSF100	 (C),	 and	 R-CPSF73	 (D)	 were	 expressed	 in	 Dmel-2	 cells	
simultaneously	 RNAi-depleted	 of	 the	 corresponding	 endogenous	 protein.	 The	 proteins	 were	 IPed,	 separated,	 and	
probed	as	described	 in	 Figure	1.	 Lane	3	of	 each	 top	panel	 shows	RNAi-depletion	of	 endogenous	CCC	 components.	
Simultaneous	RNAi-depletion	of	endogenous	CCC	factors	and	exogenous	expression	of	the	corresponding	protein	 is	
shown	in	lane	6.	The	“∗	”	denotes	a	slightly	faster	migrating	cross-reacting	band.	The	“#”	identifies	HA-CPSF73.	(E–G)	
RNAi-R	full-length	CCCs	were	IPed	as	described	in	Figure	1.	R-Symplekin	(E),	R-CPSF100	(F),	and	R-CPSF73	(G)	IP	were	
detected	with	anti-HA	antibody	(lane	4,	top	panels).	co-IP	was	assessed	with	anti-CCC	factor	antibodies.	Beads	only	
(lane	2)	and	α-Myc	(lane	3)	are	nonspecific	controls.		
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Figure	3-5	
  
	
FIGURE	5.	CCCs	with	Symplekin	C-terminal	residues	can	use	downstream	poly(A)	sites	for	H2A	mRNA	3ʹ	end	processing.	
(A)	A	schematic	of	the	histone	2A	(H2A)	mRNA	3ʹ	end	is	shown.	Cis	elements	required	for	proper	processing	are	the	
stem–loop	(SL)	and	the	histone	downstream	element	(HDE).	The	appropriate	cleavage	site	and	the	properly	processed	
H2A	3ʹ	 end	are	marked	with	 filled	arrows.	Downstream	cryptic	polyadenylation	 signals	 and	misprocessed	products	
resulting	 from	 use	 of	 these	 signals	 are	 labeled	 with	 open	 arrows.	 If	 neither	 the	 proper	 cleavage	 site	 nor	 cryptic	
polyadenylation	signals	can	be	used	for	processing,	an	extended	3ʹ	UTR	product	results	(RT).	The	3ʹ	end	labeled	DNA	S1	
nuclease	assay	probe	will	hybridize	to	all	of	these	products.	The	5ʹ	20	nt	of	the	probe	(zig-zag	line)	cannot	anneal	to	the	
H2A	3ʹ	end	products.	(B)	H2A	3ʹ	ends	in	Dmel-2	cells	containing	wild-type	and	mutant	CPSF100	CCCs	and	control	cells	
were	visualized	using	a	S1	nuclease	assay.	Addition	of	dsRNA	is	indicated	just	above	the	gel	while	expression	of	either	
full-length	or	mutant	CCC	components	is	described	above	the	solid	line.	Gel	positions	of	potential	products	are	marked	
on	the	left	with	the	same	labeling	as	in	(A).	(C	)	H2A	3ʹ	ends	in	Dmel-2	cells	containing	wild-type	and	mutant	CPSF73	
CCCs	and	control	cells	were	visualized	using	a	S1	nuclease	assay.	The	gel	is	labeled	as	in	(B).	(D)	An	S1	nuclease	assay	
was	performed	to	visualize	endogenous	H2A	mRNA	3ʹ	ends	 in	Dmel-2	cells	with	Symplekin	mutant	CCCs.	The	gel	 is	
labeled	as	in	(B).	(E)	The	percentages	of	RT,	misprocessed,	and	properly	processed	H2A	mRNAs	were	calculated	for	two	
independent	experiments.	The	averages	of	RT	and	misprocessed	products	for	each	experiment	were	plotted	with	the	
corresponding	standard	deviation	and	the	values	are	indicated	below	each	gel.	The	black	bars	are	the	percent	of	RT	
product	while	the	gray	bars	represent	percent	misprocessed	H2A	mRNA.		
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CCCs	with	the	C-terminal	218	amino	acids	of	CPSF73	misprocess	histone	mRNAs		
	
To	investigate	the	in	vivo	activity	of	CCC	containing	CPSF73	deletion	mutants,	a	
similar	approach	was	used.	An	S1	nuclease	protection	assay	using	a	probe	to	H2A	(Fig.	5A)	
shows	properly	processed	H2A	mRNA	in	wild-type	Dmel-2	cells	and	controls	treated	with	
nontargeting	 dsRNA	 (Fig.	 5C,	 lanes	 2,3).	When	 CPSF73	 is	 RNAi-depleted,	 RT	mRNA	 is	
15.0%	 of	 the	 total	 H2A	 product	 (Fig.	 5C,E).	 Few	 products	 resulting	 from	 use	 of	
downstream	cryptic	poly(A)	signals	were	observed	(5.6%).	These	data	are	consistent	with	
previously	 published	 findings	 (Sullivan	 et	 al.	 2009).	 When	 full-length	 R-	 CPSF73	 is	
expressed	simultaneously	with	RNAi-depletion	of	endogenous	CPSF73,	 the	H2A	3ʹ	end	
processing	defect	is	partially	rescued	as	only	3.0%	of	RT	H2A	is	present	in	this	sample	(Fig.	
5C,E).	Therefore,	mixed	CCC	with	full-length	R-CPSF73	are	functional.	When	CPSF73(466–
684)	 is	ex-	pressed,	13.3%	RT	H2A	misprocessing	 is	observed	 (Fig.	5C,E).	Although	this	
mutant	 forms	 CCCs	 (Fig.	 3E),	 CPSF73(466–684)	 does	 not	 rescue	 H2A	 misprocessing,	
presumably	 because	 it	 does	 not	 contain	 the	 CPSF73	 active	 site	 (Fig.	 2A).	 RT	 H2A	
misprocessed	 3ʹ	 ends	 also	 dominate	 in	 samples	where	 CPSF73(466–552)	 is	 expressed	
(17.2%	of	H2A)	(Fig.	5C,E),	indicating	that	this	mutant	does	not	rescue	H2A	misprocessing.	
Neither	 CPSF73(466–684)	 nor	 CPSF73(466–	 552)	 act	 dominantly	 as	 cells	 concurrently	
expressing	a	mutant	and	wild-type	full-length	endogenous	CPSF73	do	not	result	in	H2A	
misprocessing	(Supplemental	Fig.	2B).	As	the	dsRNA	used	for	RNAi-depletion	of	CPSF73	
targets	 the	 N-terminal	 region	 (Fig.	 2A),	 RNAi-R	 forms	 of	 CPSF73(466–684)	 and	
CPSF73(466–552)	did	not	need	to	be	constructed.	Collectively,	these	data	indicate	that	
although	CPSF73(466–	684)	can	form	CCCs,	these	CCCs	are	nonfunctional.		
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CCCs	 containing	 Symplekin	 lacking	 the	 first	 271	 amino	 acids	 use	 downstream	 cryptic	
poly(A)	sites	for	H2A	3’	end	processing	
	
We	also	investigated	the	activity	of	mutant	Symplekin	CCCs	by	visualizing	the	3ʹ	
ends	of	H2A	mRNAs	in	Dmel-2	cells	containing	these	complexes	(Fig.	5D).	RNAi-depletion	
of	Symplekin	causes	H2A	misprocessing	when	compared	with	negative	controls	(Fig.	5D,	
cf.	lane	4	to	lanes	2,3).	RT	H2A	mRNA	is	the	primary	misprocessed	H2A	product	(13.7%	of	
total	 H2A	 mRNA)	 as	 has	 been	 observed	 previously	 (Sullivan	 et	 al.	 2009).	 When	 R-
Symplekin	is	expressed	simultaneously	with	RNAi-depletion	of	endogenous	Symplekin,	RT	
H2A	mRNA	 is	 2.8%	 of	 total	 H2A	 (Fig.	 5D,E)	 indicating	 that	 exogenous	 Symplekin	 can	
partially	rescue	the	defect	caused	by	RNAi-depletion	of	endogenous	Symplekin.	As	with	
CCCs	 including	 R-CPSF73	 and	 R-CPSF100,	 R-Symplekin	 containing	 CCCs	 are	 functional.	
When	Symp(272–1165)	is	expressed	in	cells	lacking	endogenous	Symplekin,	misprocessed	
H2A	dramatically	increases	to	31.7%	and	use	of	cryptic	poly(A)	signals	is	abundant	(Fig.	
5D,E).	We	continue	to	observe	this	pattern	as	residues	are	progressively	removed	from	
the	Symplekin	C-	terminus,	although	the	total	amount	of	misprocessed	H2A	decreases;	
17.8%	of	H2A	mRNAs	are	misprocessed	by	Symp(272–1080)	containing	CCCs,	17.4%	of	
H2A	mRNAs	 are	mis-	 processed	by	 Symp(272–926)	 containing	CCCs,	 and	7.7%	of	H2A	
mRNAs	are	misprocessed	by	Symp(272–758)	(Fig.	5D,	E).	When	Symp(1–271)	is	expressed	
in	 cells	 RNAi-depleted	 of	 endogenous	 Symplekin,	 RT	 H2A	mRNA	 is	 again	 the	 primary	
misprocessing	product	 (10.0%	of	total	H2A	mRNAs)	 (Fig.	5D,E).	None	of	the	Symplekin	
mutants	 act	 dominantly	 as	 cells	 concurrently	 expressing	 a	mutant	 and	wild-type	 full-	
length	endogenous	Symplekin	do	not	result	in	H2A	misprocessing	(Supplemental	Fig.	2A).		
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These	 data	 indicate	 that	 3ʹ	 end	 misprocessed	 H2A	 mRNAs	 are	 the	 dominant	
misprocessed	 product	 in	 samples	 having	 CCCs	 with	 only	 Symplekin	 C-terminal	 amino	
acids.	These	complexes	can	use	downstream	poly(A)	signals	for	3ʹ	end	processing	of	H2A	
mRNAs.	This	is	a	novel	result	as	only	read	through	transcription	has	been	observed	when	
full-	length	CCC	components	are	RNAi-depleted	or	with	non-	functional	CCCs.		
	
DISCUSSION		
	
The	central	ideas	of	the	discussion	and	future	directions	presented	in	this	section	were	
primarily	derived	by	me.	The	most	important	aspect	of	this	paper	(the	idea	that	the	N-
terminal	271-amino	acids	of	Symplekin	are	likely	responsible	for	the	co-transcriptional	3’-
end	 processing	 of	 all	metazoan	 pre-mRNAs	while	 the	 C-terminal	 portion	 clearly	 binds	
CPSF73	and	CPSF100)	was	my	interpretation	of	the	data	generated	and	presented	here.	
In	this	section	Write-up	of	this	idea	and	other	novel	insights	from	personal	interpretation	
of	the	experimental	data	presented	in	this	section	was	a	combined	effort	between	myself	
and	Dr.	Steiniger.		
	
Pre-mRNA	3ʹ	end	processing	is	an	essential	step	in	mRNA	maturation.	The	3ʹ	ends	
of	 all	metazoan	mRNAs	 are	 cleaved	by	 the	 core	 cleavage	 complex	 (CCC)	 consisting	 of	
CPSF73,	 CPSF100,	 and	 Symplekin	 (Sullivan	 et	 al.	 2009).	 Interactions	 in	 this	 important	
complex	 have	 not	 been	 investigated.	 Furthermore,	 relationships	 between	 protein	
domains	 in	 the	 CCC	 and	 their	 function	 in	 cotranscriptional	 histone	 mRNA	 3ʹ	 end	
processing	have	not	been	characterized.	Here,	we	use	a	Dmel-2	tissue	culture	system	to	
determine	that	the	C-	terminal	∼200	amino	acids	of	CPSF73	and	CPSF100	and	amino	acids	
272–1080	of	Symplekin	are	sufficient	for	CCC	formation.	Additionally,	in	vivo	assessment	
of	mutant	CCC	activity	reveals	that	the	N-terminal	524	amino	acids	of	CPSF100	are	not	
required	 for	 formation	 of	 CCCs	 that	 properly	 process	 histone	 mRNAs.	 Lastly,	 CCCs	
containing	 Symplekin	 lacking	 the	 first	 271	 amino	 acids	 can	 use	 poly	 (A)	 signals	
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downstream	from	the	proper	cleavage	site	for	3ʹ	end	processing.	This	is	a	phenotype	also	
observed	when	his-	tone-specific	processing	factors	are	RNAi-depleted	but	in	contrast	to	
the	read	through	product	normally	produced	when	CCC	components	are	knocked	down.	
These	data	 support	a	model	 in	which	 the	 first	271	amino	acids	of	Symplekin	 facilitate	
cotranscriptional	3ʹ	end	processing	of	histone	mRNAs.		
A	novel	in	vivo	approach	to	study	CCC	interactions	and	activity		
	
We	took	a	novel	in	vivo	approach	to	investigate	both	CCC	interactions	and	mutant	
CCC	 histone	 mRNA	 3ʹ	 end	 processing.	 To	 identify	 important	 CCC	 component	 binding	
regions,	 tagged	mutant	CCC	components	were	 first	 stably	ex-	pressed	 in	Dmel-2	 cells.	
These	proteins	were	 then	 immuno-	precipitated	and	co-IP	of	endogenous	CCC-binding	
partners	was	identified.	This	approach	was	validated	using	full-length,	wild-type	tagged	
CCC	factors	for	IP	and	ensuring	co-IP	of	endogenous	CCC	components	(Fig.	1C–E).	Unlike	
previous	 investigations	 of	 interactions	within	multiprotein	 complexes	 involved	 in	 RNA	
processing,	mixed	 CCCs	 having	 both	 exogenous	 and	 endogenous	 components	 did	 not	
require	RNAi-	depletion	of	endogenous	factors	(Chen	et	al.	2013;	Lyons	et	al.	2014).		
Analysis	 of	 mutant	 CCC	 activity	 in	 this	 system	 necessitated	 an	 additional	
modification.	 Previous	 data	 indicate	 that	 misprocessed	 histone	 mRNAs	 are	 a	 small	
percentage	 of	 total	 histone	mRNA	 in	 Dmel-2	 cells	 RNAi-depleted	 of	 CCC	 components	
(Sullivan	 et	 al.	 2009).	 Therefore,	 we	 hypothesized	 that	 misprocessed	 histone	 mRNA	
resulting	from	mutant	CCC	activity	in	our	system	would	not	be	detected	in	the	presence	
of	 functional	 wild-type	 CCCs.	 To	 alleviate	 this	 problem,	 we	 constructed	 and	 stably	
expressed	 RNAi-resistant	 CCC	 mutants	 simultaneously	 with	 RNAi-depletion	 of	 the	
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corresponding	endogenous	CCC	component	(Fig.	4).	This	approach	ensured	we	were	only	
observing	activity	of	CCCs	containing	mutant	factors.	The	activity	of	these	complexes	was	
then	 assessed	 on	 H2A	 3ʹ	 ends.	 Expression	 of	 tagged	 full-length,	 wild-type	 CCC	
components	 rescued	 histone	 mRNA	 3ʹ	 end	 processing	 when	 the	 corresponding	
endogenous	 component	 was	 RNAi-depleted	 indicating	 that	 mixed	 CCCs	 are	 also	
functional	 (Fig.	 5).	 This	 novel	 Dmel-2	 cell	 culture	 system	 could	 be	 used	 to	 further	
investigate	interactions	in	the	CCC	using	CPSF73,	CPSF100,	and	Symplekin	point	mutants.	
Other	factors	required	for	cotranscriptional	histone	mRNA	3ʹ	end	processing	could	also	
be	studied	using	this	approach.		
The	C-termini	of	CPSF73,	CPSF100,	and	Symplekin	are	sufficient	for	CCC	formation		
	
Previous	to	this	study,	little	was	known	about	CCC	interactions	in	vivo.	The	three-
dimensional	structures	of	the	first	∼400	amino	acids	of	human	CPSF73	and	yeast	CPSF100	
(Mandel	 et	 al.	 2006)	 and	 the	 N-terminal	 ∼300	 amino	 acids	 of	 Drosophila	 and	 human	
Symplekin	were	individually	deter-	mined	by	X-ray	crystallography	(Kennedy	et	al.	2009;	
Xiang	et	al.	2010,	2012).	These	structures	 include	 important	 resi-	dues	comprising	 the	
CPSF73	active	site	(Fig.	2)	and	a	N-	terminal	Symplekin	HEAT	domain	interacting	with	the	
RNAPII	CTD	phosphatase	Ssu72,	but	do	not	incorporate	C-terminal	CPSF73,	CPSF100,	and	
Symplekin	 regions	 important	 for	 CCC	 formation.	 Additionally,	 previous	 bioinformatics,	
yeast-two	hybrid	and	pull-down	analyses	have	 led	to	hypotheses	that	the	C-termini	of	
CPSF100,	CPSF73,	and	Symplekin	interact	(Jenny	et	al.	1996;	Kyburz	et	al.	2003;	Dominski	
et	al.	2005b;	Zhelkovsky	et	al.	2006;	Mandel	et	al.	2008;	Ghazy	et	al.	2009),	but	these	
studies	never	included	all	three	CCC	components,	instead	focusing	on	only	two	factors.	
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The	 experiments	 described	here	 are	 the	 first	 systematic,	 in	 vivo	 approach	 to	 defining	
simultaneous	 CPSF73,	 CPSF100,	 and	 Symplekin	 binding	 interactions	 in	 the	 CCC.	 We	
provide	 evidence	 that	 amino	 acids	 272–1080	 of	 Symplekin,	 amino	 acids	 466–684	 of	
CPSF73	and	amino	acids	525–	756	of	CPSF100	are	sufficient	for	CCC	formation.		
While	 our	 data	 are	 generally	 consistent	 with	 previous	 hypotheses	 and	
observations,	our	experiments	reveal	the	following	novel	insights.	Symplekin	amino	acids	
272–1165	co-	IP	more	CPSF73	than	full-length	Symplekin,	yet	removing	85	additional	C-
terminal	amino	acids	(Symp(272–1080))	results	in	CPSF73	binding	comparable	with	full-
length	Symplekin	 (Fig.	3A,B).	These	data	 indicate	 that	while	 the	N-terminal	271	amino	
acids	 of	 Symplekin	 are	 not	 required	 for	 CCC	 formation,	 these	 residues	 inhibit	 CPSF73	
binding	to	the	C-terminal	end	of	Symplekin.	The	C-terminal	85	amino	acids	of	Symplekin	
enhance	CPSF73	binding.	Also,	CPSF73(466–	552)	maintains	binding	to	CPSF100	but	not	
Symplekin,	while	 CPSF73(466–684)	 IPs	 both	 CPSF100	 and	 Symplekin	 (Fig.	 3E,F).	 These	
data	support	a	model	in	which	CPSF73	amino	acids	466–552	interact	with	CPSF100	while	
CPSF73	amino	acids	466–684	are	required	for	binding	Symplekin.		
The	in	vivo	binding	data	presented	here,	considered	with	previous	X-ray	crystal	
structure	and	bioinformatic	analyses,	indicate	dramatic	regional	separation	of	functions	
within	 CPSF73,	 CPSF100,	 and	 Symplekin.	 Our	 N-terminal	 CPSF73(1–465)	 mutant	
encompasses	the	entire	active	site	(Fig.	2A;	Mandel	et	al.	2006),	but	these	amino	acids	
are	 not	 required	 for	 CCC	 formation	 (Fig.	 3E,F).	 The	 region	 of	 CPSF73	 responsible	 for	
endonuclease	activity	is	completely	distinct	from	the	residues	required	for	CCC	formation.	
We	hypothesize	that	use	of	an	independent	domain	for	CCC	formation	allows	substrate	
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RNA	access	 to	 the	CPSF73	 active	 site.	Additionally,	 CPSF100	amino	 acids	 648–756	are	
required	for	CCC	formation	(Fig.	3C,D).	None	of	the	residues	comprising	the	β-CASP	or	the	
metallo-β-lactamase	domain	are	contained	within	this	region	of	CPSF100.	The	first	271	
amino	ac-	ids	of	Symplekin	comprise	a	HEAT	domain	that	can	interact	with	and	stimulate	
activity	of	RNAPII	CTD	phosphatase	Ssu72	(Xiang	et	al.	2010).	This	function	of	Symplekin	
is	 con-	 fined	 to	 the	N-terminal	 region	while	 C-terminal	 residues	 are	 required	 for	 CCC	
formation.	Data	presented	here	support	a	model	 in	which	each	CPSF73,	CPSF100,	and	
Symplekin	domain	has	a	discreet	function	related	to	either	mRNA	3ʹ	end	processing	or	
CCC	formation.		
Poly(A)	sites	downstream	from	the	H2A	3ʹ	end	processing	site	are	used	inefficiently	when	
the	number	of	functional	CCCs	is	low		
	
In	 Drosophila,	 histone	 mRNAs	 are	 cotranscriptionally	 processed	 by	 the	 CCC	
followed	by	RNAPII	termination	(Fig.	6A;	Sullivan	et	al.	2009).	These	events	require	SLBP	
binding	 to	 the	 SL,	 U7	 snRNP	 interaction	with	 the	HDE	 and	 are	 coordinated	 by	 FLASH	
(Sabath	et	al.	2013).	Interaction	of	the	CCC	with	the	RNAPII	CTD	may	not	be	direct,	but	
instead	mediated	by	an	additional	protein(s).	For	instance,	Ssu72	links	Symplekin	to	the	
RNAPII	CTD	 in	yeast	and	humans	 (Xiang	et	al.	2010).	Under	normal	conditions,	RNAPII	
pauses	∼35	nt	downstream	from	the	histone	mRNA	3ʹ	end	processing	site	(Adamson	and	
Price	2003).	Presumably,	this	pause	facilitates	recruitment	of	all	trans	factors	and	allows	
for	 correct	 alignment	of	 the	RNAPII	 associated	CCC	 to	 the	 cleavage	 site.	 Processing	 is	
followed	by	transcription	termination.	These	events	result	 in	a	proper	3ʹ	processing	of	
histone	mRNAs	(Fig.	6A).		
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Previous	data	show	that	when	CCC	components	CPSF73,	CPSF100,	or	Symplekin	
are	RNAi-depleted,	all	 three	 factors	are	knocked	down,	significantly	 reducing	 the	 total	
number	of	CCCs	and	causing	H2A	3ʹ	end	misprocessing	(Wagner	et	al.	2007;	Sullivan	et	al.	
2009).	A	 low	concentration	of	CCCs	 results	 in	primarily	 read	 through	misprocessing	as	
cryptic	poly(A)	signals	downstream	from	the	proper	H2A	mRNA	cleavage	site	are	used	less	
often	(Sullivan	et	al.	2009).	This	phenotype	is	also	observed	when	CCCs	do	not	properly	
assemble	as	with	CPSF100(525–647)	and	CPSF73	(466–552)	(Fig.	3C–F).	These	mutants	
cannot	 increase	 the	 concentration	 of	 functional	 CCCs,	 therefore,	 read	 through	 H2A	
mRNAs	dominate	(Fig.	5B,C).	When	the	concentration	of	CCCs	 is	comparable	with	wild	
type	 (Fig.	 3E,F),	 but	 the	 CCCs	 do	 not	 contain	 functional	 CPSF73,	 read	 through	 H2A	
misprocessing	product	is	also	prevalent	(Fig.	5C,E).	These	data	are	in	stark	contrast	to	the	
rescue	of	H2A	misprocessing	seen	with	CCCs	containing	the	C-terminal	231	amino	acids	
of	 CPSF100	 (Fig.	 5B,E).	 The	 first	 524	 amino	 acids	 of	 CPSF100	 are	 dispensable	 for	
cotranscriptional	H2A	3ʹ	end	processing.		
These	 data	 support	 a	model	 in	which	 reducing	 the	 number	 of	 functional	 CCCs	
prevents	proper	3ʹ	end	processing	and	transcription	termination	resulting	in	H2A	mRNAs	
with	an	extended	3ʹ	UTR	(Fig.	6B).	If	a	functional	CCC	can	be	recruited	to	the	appropriate	
cleavage	site,	proper	H2A	3ʹ	ends	are	formed	as	all	other	factors	required	for	processing	
are	present.	If	a	functional	CCC	is	not	available,	cleavage	and	termination	do	not	occur	
and	RNAPII	keeps	transcribing.	Downstream	cryptic	poly(A)	signals	are	not	efficiently	used	
for	 H2A	 mRNA	 3ʹ	 end	 processing	 when	 the	 concentration	 of	 functional	 CCCs	 is	 low	
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although	poly(A)-specific	processing	 factors	are	 recruited	 to	 these	 sites	 (Sullivan	et	al.	
2009).	The	mechanistic	basis	for	this	observation	remains	an	active	area	of	investigation.		
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Figure	3-6	
  
 
FIGURE	6.	Histone	mRNA	3ʹ	end	processing	models.	(A)	A	model	for	cotranscriptional	histone	mRNA	3ʹ	end	processing	
under	normal	conditions	is	shown.	Following	transcription	of	the	cleavage	site	(black	arrow)	and	HDE,	RNAPII	pauses	
allowing	recruitment	and	proper	orientation	of	the	CCC,	SLBP,	U7	snRNP,	and	FLASH	to	the	cleavage	site.	This	results	in	
H2A	mRNA	processing	at	the	most	proximal	cleavage	site	(lightning	bolt)	and	transcription	termination.	(B)	A	model	for	
cotranscriptional	histone	mRNA	3ʹ	end	processing	under	low	CCC	concentration	conditions	is	shown.	If	a	CCC	can	be	
cotranscriptionally	 recruited	 to	 the	 cleavage	 site	 (black	 arrow),	 the	 H2A	mRNA	 3ʹ	 end	 will	 be	 properly	 processed	
(lightning	bolt).	When	no	functional	CCC	can	be	recruited,	RNAPII	continues	transcribing	and	use	of	downstream	poly(A)	
sites	 (white	 arrows)	 is	 inefficient	 resulting	 in	 read	 through	 (RT)	 H2A	mRNAs.	 (C	 )	 A	model	 for	 H2A	mRNA	 3ʹ	 end	
processing	by	CCCs	containing	Symplekin	lacking	the	first	271	amino	acids	is	shown.	A	high	concentration	of	functional	
CCCs	containing	N-terminally	truncated	Symplekin	can	use	downstream	poly(A)	sites	(white	arrows)	for	H2A	mRNA	3ʹ	
end	processing.	We	hypothesize	that	the	first	271	amino	acids	of	Symplekin	mediate	cotranscriptional	histone	mRNA	
3ʹ	end	formation.		
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CCCs	lacking	the	first	271	amino	acids	of	Symplekin	use	downstream	poly(A)	sites	for	H2A	
mRNA	3ʹ	end	processing		
	
Amino	acids	272–1165	of	Symplekin	are	sufficient	to	form	functional	CCCs	(Fig.	
3A,B).	As	these	CCCs	contain	full-	length	endogenous	CPSF73,	we	expected	H2A	mRNAs	
in	Dmel	cells	expressing	 this	Symplekin	mutant	 to	be	properly	processed.	Surprisingly,	
almost	32%	of	 the	H2A	mRNAs	 in	 these	cells	are	misprocessed	 (Fig.	5D,E).	While	 read	
through	 H2A	 mRNA	 is	 the	 dominant	 misprocessed	 product	 upon	 CCC	 factor	 RNAi-
depletion,	 CCCs	 containing	 N-terminally	 truncated	 Symplekin	 can	 efficiently	 use	
downstream	poly(A)	sites	for	H2A	mRNA	3ʹ	end	processing	(Fig.	5D,E).	The	amount	of	read	
through	product	 in	 samples	 containing	 these	mutants	 is	 approximately	 the	 same	 (Fig.	
5D,E).	 These	data	 indicate	 that	 the	ability	 to	utilize	downstream	poly(A)	 sites	 for	H2A	
mRNA	 3ʹ	 end	 processing	 is	 specific	 to	 the	 N-terminal	 271	 residues	 of	 Symplekin.	 The	
efficiency	of	CCC	formation	(Fig.	3A,B)	for	each	N-terminal	Symplekin	deletion	mutant	is	
reflected	 in	 the	 total	 amount	 of	 H2A	 3ʹ	 end	misprocessing.	 CPSF73	 is	 recruited	more	
efficiently	to	Symp(272–	1165)	than	to	full-length	Symplekin	and	we	hypothesize	that	a	
higher	concentration	of	active	CCCs	causes	increased	use	of	downstream	poly(A)	signals.	
As	 residues	 are	 deleted	 from	 the	 Symplekin	 C-terminus	 and	 less	 functional	 CCC	 are	
formed,	 total	 H2A	 3ʹ	 end	misprocessing	 decreases	 and	 the	 read	 through	H2A	mRNAs	
dominate	(Fig.	5D,E).		
Our	evidence	supports	a	model	in	which	cotranscriptional	histone	mRNA	3ʹ	end	
processing	is	mediated	by	the	N-terminal	271	amino	acids	of	Symplekin	(Fig.	6C).	When	
the	number	of	 functional	CCCs	 is	high,	but	Symplekin	amino	ac-	 ids	1–271	are	absent,	
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cryptic	 downstream	 poly(A)	 signals	 can	 be	 efficiently	 utilized	 for	 H2A	 mRNA	 3ʹ	 end	
processing.	This	is	in	contrast	to	read	through	products	observed	when	the	concentration	
of	 functional	 CCCs	 is	 low	 but	 full-length	 Symplekin	 is	 present	 (Fig.	 6B).	 Previous	
experiments	 specify	 a	 role	 for	 the	N-terminal	 region	of	 Symplekin	 in	 cotranscriptional	
polyadenylation.	 Amino	 acids	 30–340	 of	 human	 Symplekin	 were	 cocrystallized	 with	
RNAPII	CTD	phosphatase	Ssu72	and	a	RNAPII	CTD	peptide	supporting	strong	interactions	
between	 these	proteins	 (Xiang	et	 al.	 2010).	 The	human	Symplekin	N-terminal	 domain	
inhibits	transcription	coupled	polyadenylation	in	vitro	(Xiang	et	al.	2010).	Additionally,	the	
use	 of	 downstream	 poly(A)	 sites	 for	 H2A	 mRNA	 3ʹ	 end	 processing	 observed	 for	 N-
terminally	 truncated	Symplekin	containing	CCCs	 is	 similar	 to	 the	processing	pattern	of	
H2A	mRNAs	when	histone-specific	 processing	 factors	 SLBP,	U7	 snRNP,	 and	 FLASH	 are	
RNAi-depleted	(Lanzotti	et	al.	2002;	Tatomer	et	al.	2014).	SLBP,	U7	snRNP,	and	FLASH	are	
hypothesized	to	be	required	for	cotranscriptional	3ʹ	end	processing	of	histone	mRNAs.	
Taken	together,	these	data	best	support	two	hypotheses.	Either	the	first	271	amino	acids	
of	Symplekin	are	required	for	interaction	with	histone-specific	3ʹ	end	processing	factors	
or	they	mediate	interaction	indirectly	or	directly	with	RNAPII.	These	ideas	are	being	tested	
in	vivo	using	our	Drosophila	tissue	culture	system.		
MATERIALS	AND	METHODS	
	
All	materials	and	methods	were	initially	written	by	me	and	revised	by	Dr.	Steiniger.	
	
Gene	cloning	and	plasmid	construction		
	
Full-length	CPSF73,	CPSF100,	and	Symplekin	were	PCR	amplified	from	Drosophila	
gene	 collection	 (DGC)	 clones	 (Open	 Biosystems)	 using	 specific	 primers.	 The	 amplified	
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genes	 were	 directionally	 cloned	 into	 pENTR	 D-TOPO	 (Invitrogen)	 to	 create	 CPSF73,	
CPSF100,	 and	 Symplekin::pENTRD-TOPO.	 Proper	 gene	 insertion	 was	 confirmed	 via	
restriction	 digest	 and	 Sanger	 sequencing.	 CPSF73,	 CPSF100,	 and	 Symplekin::pENTRD-
TOPO	were	each	re-	combined	with	pAHW	and	pAWH	destination	vectors	 (Drosophila	
Gateway	 vector	 collection,	 Carnegie	 Institution	 for	 Science)	 using	 Clonase	 II	 (Life	
Technologies).	 Proper	 gene	 recombination	 was	 confirmed	 via	 restriction	 digest	 and	
Sanger	sequencing.	Deletion	mutants	for	each	of	the	three	CCC	proteins	were	cloned	and	
recombined	as	described	for	their	FL	counterparts.		
RNAi-resistant	(RNAi-R)	Symplekin,	CPSF73,	and	CPSF100	were	designed	using	an	
online	 tool	 described	 in	 Schulz	 et	 al.	 (2009).	 This	 tool	 changes	wobble	 bases	within	 a	
targeted	area	while	also	being	sensitive	to	codon	bias.	A	DNA	fragment	corresponding	to	
the	∼500	bp	target	region	was	synthesized	as	a	GeneArt	Strings	DNA	Fragment	by	Life	
Technologies.	 Each	 RNAi-R	 GeneArt	 String	 and	 corresponding	 Symplekin,	 CPSF73,	 or	
CPSF100::pENTRD-TOPO	 were	 digested	 with	 restriction	 enzymes	 and	 the	 RNAi-R	
fragment	was	substituted	for	 the	wild-type	piece	to	create	RNAi-R	Symplekin,	CPSF73,	
and	CPSF100::pENTRD-TOPO.	 Ligation	was	 confirmed	 via	 restriction	digest	 and	 Sanger	
sequencing.	 RNAi-R	 Symplekin,	 CPSF73,	 and	 CPSF100::pENTRD-TOPO	 were	 each	
recombined	with	pAHW	and	pAWH	destination	vectors	as	described	above.	Proper	re-	
combination	was	again	confirmed	via	restriction	digest	and	Sanger	sequencing.		
Creation	of	stable	Drosophila	Dmel-2	tissue	culture	lines		
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Full-length/mutant	 CCC	 factor::pAHW	 or	 full-length/mutant	 CCC	 factor::pAWH	
were	 transfected	 into	 Drosophila	 Dmel-2	 cells	 with	 Effectene	 Transfection	 Reagent	
(Qiagen)	 according	 to	 the	 manufacturer’s	 protocol.	 The	 pCoBlast	 vector	 (Invitrogen)	
containing	 a	 Blasticidin	 resistance	 gene	 was	 cotransfected	 to	 enable	 selection	 of	
successfully	transfected	cells.	Cells	were	grown	in	SF-900	II	SFM	(Gibco)	and	maintained	
at	 27°C	 under	 normal	 atmospheric	 condi-	 tions.	 Forty-eight	 hours	 post-transfection,	
Blasticidin	(25	μg/mL)	was	added	to	the	media	to	select	for	stably	transfected	cells.	Cells	
were	split	and	passaged	into	fresh	selective	media	every	5	d	to	a	con-	centration	of	1	×	
106/mL.	 Stable	 transfection	 was	 confirmed	 via	 Western	 blot	 with	 anti-HA	 antibody	
(Covance).		
RNAi,	whole-cell	lysate	preparation,	nuclear	extract	preparation	and	RNA	isolation		
	
RNAi	was	performed	as	described	(Sullivan	et	al.	2009).	On	Day	5,	the	cells	were	
counted	with	a	Nexcelom	cell	 counter	and	harvested	 for	analysis.	 To	make	whole-cell	
lysates,	5	×	106	RNAi-depleted	or	control	cells	were	lysed	with	RIPA	buffer	(50	mM	Tris–
HCl	(pH	8),	150	mM	NaCl,	1%	Nonidet	P-40,	0.25%	Na	deoxycholate)	plus	5	μL	100×	Halt	
Protease	inhibitor	(Thermo	Scientific),	and	rotated	at	4°C	for	10	min	and	centrifuged	for	
15	min	at	14,000	rpm	to	remove	cellular	debris.	The	supernatant	was	transferred	to	a	
new	 tube	 and	 filtered	 through	 a	 1	 mL	 syringe	 with	 a	 26	 Gauge	 needle	 to	 shear	 the	
chromatin.	NEs	were	prepared	as	described	(Sullivan	et	al.	2009)	from	1	×	108	cells	and	
then	flash	frozen	in	liquid	N2	and	stored	at	−80°C.	Whole-cell	lysates	and	NEs	were	used	
for	immuno-	precipitations	(IPs)	and	protein	expression	analysis.	Total	RNA	was	extracted	
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from	RNAi-depleted	or	control	cells	with	TRIzol	Reagent	(Sigma)	as	described	previously	
for	use	in	S1	assays	(Sullivan	et	al.	2009).		
Antibodies		
	
Monoclonal	 and	 polyclonal	 HA	 antibodies	 (Cat	 #s	 MMS-101R	 and	 PRB-101C,	
respectively,	Covance)	were	used	for	both	IP	(3	μL)	and	WB	(1:1000).	Anti-CPSF73,	anti-
Symplekin,	and	anti-CPSF100	antibodies	were	described	previously	(Sullivan	et	al.	2009;	
Yang	et	al.	2009).	For	WB,	antibodies	were	used	at	1:1000.		
Immunoprecipitation	and	S1	nuclease	protection	assay		
	
IP	of	HA-tagged	proteins	were	performed	as	described	(Sullivan	et	al.	2009).	S1	
nuclease	protection	assay	was	also	performed	as	de-	scribed	(Sullivan	et	al.	2009).		
IP	quantitation		
	
Blots	were	scanned	at	600	PPI	and	analyzed	using	ImageJ	software.	Intensity	of	
protein	bands	representing	IP	or	co-IP	were	determined	and	compared	with	the	intensity	
of	the	corresponding	input	band	(representing	5%	of	the	sample).	The	ratio	of	IP	or	co-IP	
intensity	 to	 input	 intensity	 was	multiplied	 by	 5	 to	 determine	 the	 percentage	 of	 total	
protein	immunoprecipitated	from	the	sample.		
S1	quantification		
	
Two	 independent	experiments	were	quantitated	for	each	S1	experiment.	Dried	
6%	Urea/TBE	 sample	 gels	were	placed	on	phosphoscreens	 overnight.	 Phosphoscreens	
were	scanned	using	a	STORM	Scanner	and	images	were	saved	as	TIFF	files.	The	TIFF	files	
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were	 imported	 into	 ImageJ	 software	 and	 subsequently	 analyzed.	 Peak	 areas	 were	
determined	for	bands	corresponding	to	RT,	misprocessed	and	properly	processed	H2A	
mRNAs.	The	sum	total	of	all	peaks	 in	each	lane	was	then	determined	and	the	area	for	
each	peak	(band)	was	divided	by	the	sum	total	of	peaks	in	that	lane	to	give	a	percentage.	
The	percentages	were	averaged	and	the	standard	deviation	calculated	for	all	products	in	
each	sample.		
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SUPPLEMENTAL	MATERIAL	
SUPPLEMENTAL	FIGURE	1		
 
	
Figure	 1.	 RNAi-resistant	 (RNAi-R)	 CCC	 deletion	 mutants	 are	 expressed	 during	 simultaneous	 knockdown	 of	
corresponding	endogenous	proteins.	RNAi-R	CCC	deletion	mutants	were	constructed	as	described	in	Figure	4	or	were	
RNAi-R	because	the	dsRNA	targeted	region	was	not	contained	in	the	deletion	(Figure	2).	HA-tagged,	N-	and	C-terminal	
RNAi-R	deletion	mutants	of	(A)	Symplekin	(B)	CPSF100	and	(C)	CPSF73	were	expressed	in	Dmel-2	cells	simultaneously	
RNAi-depleted	of	the	corresponding	endogenous	protein.	Depletion	of	endogenous	protein	in	each	mutant	cell	line	was	
compared	to	no	dsRNA	and	non-specific	(LacZ)	dsRNA	controls.		
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SUPPLEMENTAL	FIGURE	2	
	
	
Figure	2.	Symplekin	and	CPSF73	deletion	mutants	do	not	act	dominantly	 in	the	presence	of	wild	type,	 full	 length	
endogenous	CCC	components.	HA-tagged	CPSF73	and	Symplekin	deletion	mutants	were	expressed	in	Dmel-2	cells	in	
the	absence	of	RNAi-depletion	of	endogenous	CCC	components.	H2A	3’	ends	were	assessed	by	S1	assay	as	in	Figure	5.	
Gels	are	labeled	as	in	Figures	5B-5D.	Samples	having	CPSF73	(A)	and	Symplekin	(B)	and	mutants	showed	only	properly	
processed	H2A	mRNA.			
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CHAPTER	4:	Discussion	and	Future	Directions	
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Pre-mRNA	3ʹ	end	processing	is	an	essential	step	in	mRNA	maturation.	The	3ʹ	ends	
of	 all	metazoan	mRNAs	 are	 cleaved	by	 the	 core	 cleavage	 complex	 (CCC)	 consisting	 of	
CPSF73,	 CPSF100,	 and	 Symplekin	 (Sullivan	 et	 al.	 2009).	 Interactions	 in	 this	 important	
complex	had	not	been	investigated,	and	the	relationships	between	protein	domains	 in	
the	CCC	and	their	function	in	cotranscriptional	histone	mRNA	3ʹ-end	processing	had	not	
yet	been	characterized.	Here,	we	used	a	Dmel-2	tissue	culture	system	that	enabled	us	to	
determine	that	the	C-	terminal	∼200	amino	acids	of	CPSF73	and	CPSF100	and	amino	acids	
272–1080	of	Symplekin	are	sufficient	for	CCC	formation.	Additionally,	in	vivo	assessment	
of	mutant	CCC	activity	revealed	that	the	N-terminal	524	amino	acids	of	CPSF100	are	not	
required	 for	 formation	 of	 CCCs	 that	 properly	 process	 histone	 mRNAs.	 Lastly,	 CCCs	
containing	C-terminal	Symplekin	(272-1165)	can	use	poly(A)	signals	downstream	from	the	
proper	 cleavage	 site	 for	 3’-end	 processing.	 This	 is	 a	 phenotype	 also	 observed	 when	
histone-specific	processing	factors	are	RNAi-depleted	but	in	contrast	to	the	read	through	
product	 normally	 produced	 when	 CCC	 components	 are	 knocked	 down.	 These	 data	
support	 a	 model	 in	 which	 the	 N-terminal	 271	 amino	 acids	 of	 Symplekin	 facilitate	
cotranscriptional	3’-end	processing	of	histone	mRNAs.		
I	took	a	novel	in	vivo	approach	to	investigate	both	CCC	interactions	and	mutant	
CCC	histone	mRNA	3ʹ-end	processing.	To	identify	important	CCC	factor	binding	regions,	
tagged	CCC	 factor	mutants	were	 first	 stably	expressed	 in	Dmel-2	 cells.	 These	proteins	
were	 then	 immunoprecipitated	 and	 co-IP	 of	 endogenous	 CCC-binding	 partners	 were	
identified.	This	approach	was	validated	using	full-length,	wild-type	tagged	CCC	factors	for	
IP	and	ensuring	co-IP	of	endogenous	CCC	components.	Unlike	several	previous	studies	
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investigating	the	interactions	within	multiprotein	complexes	involved	in	RNA	processing,	
mixed	CCCs	having	both	exogenous	and	endogenous	components	did	not	require	RNAi-
depletion	of	endogenous	factors	in	order	to	observe	binding	patterns	(Chen	et	al.	2013;	
Lyons	et	al.	2014).		
Analysis	 of	 mutant	 CCC	 activity	 in	 this	 system	 necessitated	 an	 additional	
modification.	 Previous	 data	 indicate	 that	 misprocessed	 histone	 mRNAs	 are	 a	 small	
percentage	 of	 total	 histone	mRNA	 in	 Dmel-2	 cells	 RNAi-depleted	 of	 CCC	 components	
(Sullivan	 et	 al.	 2009).	 Therefore,	 we	 hypothesized	 that	 misprocessed	 histone	 mRNA	
resulting	from	mutant	CCC	activity	in	our	system	would	not	be	detected	in	the	presence	
of	functional	wild-type	CCCs.	To	alleviate	this	problem,	I	constructed	and	stably	expressed	
RNAi-resistant	 CCC	 mutants	 simultaneously	 with	 effective	 RNAi-depletion	 of	 the	
corresponding	endogenous	CCC	component.	This	approach	ensured	we	were	observing	
activity	 of	mutant	 CCC	 factors	 alone.	We	must,	 however,	 address	 the	 fact	 that	 RNAi-
mediated	protein	KD	does	not	fully	prevent	expression	of	the	targeted	protein.	Thus,	even	
in	 cells	 treated	with	dsRNA	 intended	 to	 knock-down	a	 targeted	protein	 there	 is	 likely	
some	residual	amount	of	wild-type	protein	being	expressed.	This	then	would	allow	WT	
CCCs	to	form	and	properly	cleave	histone	mRNAs.	This	explains	why	even	in	the	presence	
of	RNAi	the	vast	majority	of	histone	pre-mRNAs	are	processed	correctly.	Despite	the	fact	
that	RNAi	is	not	100%	effective,	this	approach	allowed	the	phenotypes	associated	with	
each	mutant	CCC	to	be		observed	via	the	use	of		an	S1	nuclease	assay.	Expression	of	tagged	
full-length,	wild-type	CCC	components	rescued	histone	mRNA	3ʹ-end	processing	when	the	
corresponding	endogenous	component	was	RNAi-depleted,	 indicating	that	mixed	CCCs	
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are	also	functional.	Thus,	this	novel	research	has	provided	a	proof	of	concept	Dmel-2	cell	
culture	system	in	which	an	endogenous	cellular	protein,	known	to	interact	and	bind	to	
another	protein	in	a	complex,	can	be	replaced	with	an	exogenously	expressed	mutated	
version	 in	 order	 to	 test	 for	 functional	 consequences	 of	whatever	 cellular	 process	 it	 is	
involved	in.	Additionally,	this	system	can	be	employed	to	further	investigate	interactions	
within	 the	 CCC	 using	 CPSF73,	 CPSF100,	 and	 Symplekin	 point	 mutants,	 or	 to	 test	
interactions	between	the	CCC	and	other	cleavage	and	polyadenylation	processing	factors.	
This	 system	 could	 also	 be	 used	 to	 look	 at	 how	 other	 protein	 factors	 required	 for	
cotranscriptional	histone	mRNA	3ʹ-end	processing	contribute	to	the	processing	event.		
The	 C-termini	 of	 CPSF73,	 CPSF100,	 and	 Symplekin	 are	 sufficient	 for	 CCC	 formation:	
Significance	of	findings	
		
Previous	to	this	study,	little	was	known	about	CCC	interactions	in	vivo.	The	three-
dimensional	 structure	 of	 the	 Drosophila	 mRNA	 core	 cleavage	 complex	 had	 been	
characterized	based	on	X-ray	crystallography	of	the	N-terminal	∼400	amino	acids	of	both	
human	CPSF73	and	yeast	CPSF100	Fig	1-O	 (Mandel	et	al.	2006;	 	 (Kennedy	et	al.	2009;	
Xiang	et	al.	2010,	2012),	and	the	N-terminal	∼300	amino	acids	of	Drosophila	and	human	
Symplekin.	These	structures	were	important	for	characterizing	CCC	binding	interactions	
as	they	included	the	specific	residues	comprising	the	CPSF73	active	site	and	a	N-	terminal	
Symplekin	 HEAT	 domain,	 My	 hypothesis	 is	 that	 the	 Symplekin	 HEAT	 domain	 directly	
contacts	the	RNAPII	CTD	phosphatase	Ssu72.	These	crystal	structures	do	not,	however,	
incorporate	 the	 C-terminal	 regions	 of	 CPSF73,	 CPSF100,	 and	 Symplekin.	 Additionally,	
previous	bioinformatics,	yeast-two	hybrid	and	pull-down	analyses	have	led	to	hypotheses	
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that	the	C-termini	of	CPSF100,	CPSF73,	and	Symplekin	interact	(Jenny	et	al.	1996;	Kyburz	
et	al.	2003;	Dominski	et	al.	2005b;	Zhelkovsky	et	al.	2006;	Mandel	et	al.	2008;	Ghazy	et	al.	
2009),	but	these	studies	did	not	include	all	three	CCC	components	together	in	a	complex	
of	three,	instead	focusing	on	only	two	factors.	The	experiments	described	here	are	the	
first	 systematic,	 in	 vivo	 approach	 to	 defining	 simultaneous	 CPSF73,	 CPSF100,	 and	
Symplekin	binding	 interactions	within	 the	CCC.	We	provide	evidence	 that	amino	acids	
272–1080	of	Symplekin,	amino	acids	466–684	of	CPSF73	and	amino	acids	525–	756	of	
CPSF100	are	sufficient	for	CCC	formation.	While	our	data	are	generally	consistent	with	
previous	 hypotheses	 and	 observations,	 our	 experiments	 reveal	 the	 following	 novel	
insights.	Symplekin	amino	acids	272–1165	co-	IP	more	CPSF73	than	full-length	Symplekin,	
yet	removing	85	additional	C-terminal	amino	acids	(Symp(272–1080))	results	in	CPSF73	
binding	 comparable	with	 full-length	 Symplekin.	 These	 data	 indicate	 that	while	 the	N-
terminal	271	amino	acids	of	Symplekin	are	not	required	for	CCC	formation,	these	residues	
may	play	 a	 role	 to	 inhibit	 CPSF73	binding	 to	 the	 C-terminal	 end	of	 Symplekin.	 The	C-
terminal	 85	 amino	 acids	 of	 Symplekin	 appear	 to	 enhance	 CPSF73	 binding.	 Also,	
CPSF73(466–	552)	maintains	binding	to	CPSF100	but	 it	does	not	bind	Symplekin,	while	
CPSF73(466–684)	IPs	both	CPSF100	and	Symplekin.	These	data	support	a	model	in	which	
CPSF73	amino	acids	466–552	interact	with	CPSF100	while	CPSF73	amino	acids	466–684	
are	required	for	binding	Symplekin.	The	in	vivo	binding	data	presented	here,	considered	
with	 previous	 X-ray	 crystal	 structure	 and	 bioinformatic	 analyses,	 indicate	 dramatic	
regional	 separation	 of	 functions	 within	 CPSF73,	 CPSF100,	 and	 Symplekin	 based	 on	
primary	 and	 secondary	 protein	 structure.	 Our	 N-terminal	 CPSF73(1–465)	 mutant	
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encompasses	the	entire	active	site	(Mandel	et	al.	2006),	but	these	amino	acids	are	not	
required	for	CCC	formation.	The	region	of	CPSF73	responsible	for	endonuclease	activity	
is	completely	distinct	from	the	residues	required	for	CCC	formation.	We	hypothesize	that	
use	of	 an	 independent	 domain	 for	 CCC	 formation	 allows	 substrate	RNA	access	 to	 the	
CPSF73	 active	 site.	 Additionally,	 CPSF100	 amino	 acids	 648–756	 are	 required	 for	 CCC	
formation,	yet	these	C-terminal	residues	are	distinct	from	the	residues	comprising	the	β-
CASP	or	the	metallo-β-lactamase	domain.	The	two	domains	are	contained	within	the	N-
terminal	~2/3	of	the	protein..	X-ray	crystal	structure	data	reveals	the	first	271	amino	acids	
of	 Symplekin	 comprise	a	HEAT	domain,	which	has	 since	been	 shown	 to	be	capable	of	
interacting	with	and	stimulating	activity	of	the	RNAPII	CTD	phosphatase	Ssu72	(Xiang	et	
al.	2010).	It	appears	this	function	of	Symplekin	is	confined	to	the	N-terminal	region	while	
specific	 C-terminal	 residues	 are	 required	 for	 CCC	 formation.	 The	 data	 presented	 here	
support	a	model	in	which	known	domains	of	each	CPSF73,	CPSF100,	and	Symplekin	have	
a	 distinct	 and	 discreet	 function	 related	 to	 either	 mRNA	 3ʹ	 end	 processing	 or	 CCC	
formation.		
	
CCCs	 lacking	 the	 N-terminal	 271	 amino	 acids	 of	 Symplekin	 use	 cryptic	 poly(A)	 sites	
downstream	 of	 the	 proper	 H2A	mRNA	 3’	 end	 processing	 site	 due	 to	 cotranscriptional	
processing	defects	
	
Amino	acids	272–1165	of	Symplekin	are	sufficient	for	forming	functional	CCCs.	As	
these	CCCs	 contain	 full-length	endogenous	CPSF73,	we	expected	H2A	mRNAs	 in	Dmel	
cells	expressing	this	Symplekin	mutant	to	be	properly	processed.	Surprisingly,	almost	32%	
of	the	H2A	mRNAs	in	these	cells	are	misprocessed.	While	read	through	(RT)	H2A	mRNA	is	
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the	dominant	misprocessed	product	upon	CCC	factor	RNAi-depletion,	CCCs	containing	N-
terminally	truncated	Symplekin	(lacks	the	first	271	a.a.	of	the	protein)	can	efficiently	use	
downstream	poly(A)	sites	for	H2A	mRNA	3ʹ	end	processing.	The	amount	of	read	through	
product	 in	 samples	 containing	 these	mutants	 is	 approximately	 the	 same.	 These	 data	
indicate	 that	 the	 ability	 to	 utilize	 downstream	 poly(A)	 sites	 for	 H2A	 mRNA	 3ʹ-end	
processing	 is	 specific	 to	 (and	 a	 primary	 function	 of)	 the	 N-terminal	 271	 residues	 of	
Symplekin.	 The	 efficiency	 of	 CCC	 formation	 for	 each	 N-terminal	 Symplekin	 deletion	
mutant	is	reflected	in	the	total	amount	of	H2A	3ʹ-end	misprocessing.	According	to	our	co-
IP	data,	CPSF73	gets	recruited	more	efficiently	 to	Symp(272–	1165)	 than	to	 full-length	
Symplekin,	possibly	due	to	missing	secondary	structures	creating	some	degree	of	steric	
hindrance.	 Thus	 we	 hypothesize	 that	 a	 higher	 cellular	 concentration	 of	 active	 CCCs,	
possessing	 a	 functioning	CPFS73	but	 an	N-terminally	 truncated	 Symplekin,	 caused	 the	
increased	use	of	downstream	cryptic	poly(A)	signals	revealed	by	the	S1	nuclease	assays.	
As	residues	are	deleted	from	the	Symplekin	C-terminus,	which	is	the	region	required	for	
binding	and	CCC	complex	formation,	presumably	less	and	less	functional	CCCs	are	formed	
and	so	total	H2A	3ʹ-end	misprocessing	decreases	and	the	read	through	H2A	mRNAs,	which	
lack	any	form	of	processing,	dominate.		
Our	experimental	evidence	supports	a	model	in	which	cotranscriptional	histone	
mRNA	3ʹ	end	processing	 is	mediated	by	the	N-terminal	271	amino	acids	of	Symplekin.	
When	 the	 number	 of	 functional	 CCCs	 (possessing	 a	 full-length	 CPSF73)	 is	 high	 but	
Symplekin	 is	 lacking	 the	 first	 271	 amino	 acids,	 cryptic	 downstream	 poly(A)	 signals	
suddenly	can	be	efficiently	utilized	for	H2A	mRNA	3ʹ-end	processing.	This	is	in	contrast	to	
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read	through	products	observed	when	the	concentration	of	functional	CCCs	 is	 low	but	
full-length	Symplekin	is	present.	Previous	experiments	specify	a	role	for	the	N-terminal	
region	of	Symplekin	in	cotranscriptional	cleavage	and	polyadenylation.	Experiments	have	
shown	that	amino	acids	30–340	of	human	Symplekin	were	co-crystallized	with	RNAPII	CTD	
phosphatase	Ssu72	and	a	RNAPII	CTD	peptide,	lending	strong	support	to	the	notion	that	
Symplekin	does	 indeed	 interact	with	 the	RNAPII	CTD.	This	 interaction	 is	possibly	quite	
transient	due	to	the	nature	of	Ssu72	phosphatase	(Xiang	et	al.	2010).	It	must	be	noted,	
however,	 that	 the	 N-terminal	 domain	 of	 human	 Symplekin	 was	 shown	 to	 inhibit	
transcription	coupled	polyadenylation	in	vitro	(Xiang	et	al.	2010).	The	key	to	addressing	
this	possible	contradiction	to	the	idea	I	am	proposing	is	based	on	the	fact	that	all	of	the	
experiments	 from	 the	 study	 were	 done	 in	 vitro,	 not	 in	 vivo.	 Additional	 evidence	
supporting	 the	 co-transcriptional	 role	 for	 the	 N-terminal	 of	 Symplekin	 is	 that	 use	 of	
downstream	 poly(A)	 sites	 for	 H2A	mRNA	 3ʹ-end	 processing	 observed	 for	 N-terminally	
truncated	Symplekin	containing	CCCs	is	similar	to	the	processing	pattern	of	H2A	mRNAs	
when	 histone-specific	 processing	 factors	 SLBP,	 the	 U7	 snRNP,	 and	 FLASH	 are	 RNAi-
depleted	(Lanzotti	et	al.	2002;	Tatomer	et	al.	2014).	Protein	factors	SLBP,	U7	snRNP,	and	
FLASH	are	hypothesized	to	be	required	for	cotranscriptional	3’-end	processing	of	histone	
mRNAs.	Taken	together,	these	data	best	support	the	following	hypothesis:	The	first	271	
amino	acids	of	Symplekin	are	required	for	CCC	interaction	with	the	RNAPII	CTD	(either	
directly	or	indirectly),	and	this	interaction	subsequently	promotes	CCC	interaction	with	
histone-specific	 3’-	 end	 processing	 factors.	 This	 combination	 of	 interactions	 promotes	
proper	cleavage	of	histone	pre-mRNAs	into	mature	histone	mRNAs.		
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As	a	recap,	regulation	of	gene	expression	is	vital	for	proper	cellular	differentiation,	
cellular	proliferation,	and	organismal	development.	At	the	post-transcriptional	level	this	
regulation	involves	proper	processing	of	pre-mRNAs.	There	exist	two	types	of	cellular	pre-
mRNAs:	 histone	 pre-mRNAs	 and	 poly(A)	 pre-mRNAs.	 Both	 types	 of	 pre-mRNAs	 are	
processed	by	numerous	large	multi-protein	complexes	as	well	as	individual	RNA	binding	
proteins.	The	core	cleavage	complex	is	comprised	of	CPSF73,	CPSF100,	and	Symplekin,	a	
trio	of	pre-mRNA	processing	proteins	 that	have	been	 shown	 to	be	dependent	on	one	
another	 for	 stabilization.	 This	 complex	 is	 required	 for	 the	 3’-end	 processing	 of	 all	
metazoan	 pre-mRNAs,	 thus,	 identifying	 binding	 interactions	 within	 this	 complex	 and	
characterizing	its	functionality	on	histone	and	poly(A)	mRNA	processing	is	important	so	
that	we	have	a	correct	map	detailing	how	proper	pre-mRNA	are	processing	at	the	3’-end.	
This	work	was	completed	in	the	model	organism	Drosophila	melanogaster	(a.k.a.	
the	fruit	fly),	which	utilized	a	user	friendly	embryonic	tissue	culture	cell	line	known	as	S2	
or	Dmel-2	cells	intended	for	research	purposes.	Working	in	this	model	system	provided	
ease	of	study	and	system	manipulation	for	characterizing	the	core	cleavage	complex.	The	
work	performed	and	the	results	obtained	from	using	this	model	system	are	translational,	
in	that,	this	complex	of	proteins	has	homologs	in	human	cells.	Thus,	should	the	need	arise	
scientists	could	examine	this	complex	in	human	cell	lines,	utilizing	the	results	of	this	study	
for	their	needs.		
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